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ABSTRACT
PROFILE OF CL 218,872, A N ON
-BENZODIAZEPINE
ANXIOLYTIC OF THE TRIAZOLOPYRIDAZ INE CLASS
(September, 1984)
John F. McElroy, B.S., University of Massachusetts
Ph.D., University of Massachusetts
Directed by: Professors Robert S. Feldman
and Jerrold S. Meyer
There exist in brain at least two pharmacologically
distinct types among benzodiazepine (BDZ) receptors. Type I
receptors show a high affinity for both BDZs and triazolo-
pyridazines (TPZ), a class of non-BDZ anxiolytic compounds.
Type II receptors show a high affinity for BDZs, but a low
affinity for TPZs. Because TPZs have a selective affinity
for Type I BDZ receptors, they afford a unique opportunity
to examine whether various BDZ actions are mediated via
this BDZ receptor subtype.
In experiment 1 rats were trained to discriminate the
BDZ chlordiazepoxide (CDP) from saline. The TPZ CL
218,872 generalized to the CDP discriminative stimulus, an
effect antagonized by the concurrent admisi stration of
pentylenetetrazol or amphetamine, but not by bicuculline or
strychnine. These results indicate that the discriminative
stimulus and anticonvulsant effects produced by BDZs may be
mediated via activation of Type I BDZ receptors.
vi
In the next experiment acute injection of CDP
decreased the turnover rate in brain of serotonin (5-HT),
but not that of catecholamines (CA), while chronic CDP
treatment decreased the turnover rates of both transmit-
ters. In contrast, acutely or chronically administered CL
218,872 did not alter baseline 5-HT or CA turnover rates.
These results indicate that stimulation of Type I receptors
is not sufficient to decrease 5-HT and CA turnover rates,
and more importantly question the long held belief that
BDZs exert their anxiolytic and depressant effects via
reductions in 5-HT and CA turnover respectively.
In the last experiment a low dose of CDP attenuated
the increase in serum corticosterone (CS) produced by
exposure to a novel environment plus sound stimulation.
Somewhat higher doses elevated CS levels in unstressed
rats. Parallel results were obtained after central drug
injection CL 218,872, however, did not lower the CS eleva-
tion produced by stress, and also failed to alter baseline
CS levels in unstressed rats. Furthermore, the CDP effect
in stressed rats was fully prevented by PK 11195, a recep-
tor antagonist specific for peripheral- type BDZ receptors,
but not by Ro 15-1788, an antagonist specific for central-
type BDZ receptors. Taken together, these results implicate
peripheral- type BDZ receptors in brain as the target sites
through which BDZs influence CS secretion.
vii
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CHAPTER I
GENERAL INTRODUCTION
Since the introduction of chlordiazepoxide (Librium)
and diazepam (Valium) in the early 1960's, the 1,4-
benozdiazepines (BDZs) have been the most widely prescribed
drugs in medicine. BDZ sales peaked between 1 97 3 and 1975
,
with approximately 85 million prescriptions filled each
year. Diazepam alone accounted for fully two-thirds of
these sales. Although BDZs continue to account for roughly
80 percent of all minor tranquilizer and 50 percent of all
psychoactive drug prescriptions filled annually (Harvey,
1980; Rickels, 1980), the overall use of sedative-hypnotic-
anxiolytics has declined dramatically since 1975, with
diazepam sales down from 62 million prescriptions (three
billion pills) per year to "only" 45 and 31 million
prescriptions filled in 1978 and 1 98 1 respectively (Colen,
1982). This 50 percent drop in prescription drug use has
been attributed to better education of both doctors and the
general public about the dangers of some drugs, and of
possible alternative non-drug therapy.
The most characteristic effect that the BDZs produce
1
2at the smallest pharmacologically active doses is
antianxiety and disinhibi tion of certain behaviors. in
several animal models, the type of behavior that originally
has a high frequency of occurrence but that is subsequently
suppressed by environmental- or experimenter-induced
manipulations seems to be sensitive to the pharmacological
effects of these compounds (Geller and Seifter, I960;
Zbinden and Randall, 1967; Margules and Stein, 1968). For
several qualitatively different conditions which meet this
description, BDZs appear to have a general disinhibitory
action which can be measured as a partial or complete
restoration of responding to presuppression levels.
In addition to their use in the clinical treatment of
anxiety, various members of this series are also used for
their anticonvulsant, muscle relaxant, and sedative-hypnotic
effects. In addition to chlordiazepoxide and diazepam,
oxazepam (Serax; introduced in 1964) and clorazepate
(introduced in 1977) are prescribed primarily for their
antianxiety effects (Warner, 1965; Shader and Greenblatt,
1977). Flurazepam (Dalmane; introduced in 1970) was the
first BDZ in the U.S. indicated specifically for the
treatment of insomnia, and has subsequently accounted for
fully half of all sleeping pill prescriptions (Smith,
1979). Although flurazepam is still the most widely
3prescribed sedative-hypnotic, temazepam and triazolam were
introduced as hypnotic agents in 1981, and at least five
other BDZ derivatives (quazepam, brotizolam, estazolam,
midazolam, and lormetazepam ) are currently under investi-
gation as sleep-inducing medications (Greenblatt et al.,
1982) .
Despite the clinical popularity of BDZs, their site
and molecular mechanisms of action remain somewhat unclear.
"Mechanisms" is used in the plural because the actions of a
psychotropic drug may be expressed on multiple levels,
ranging from behavioral studies to receptor binding assays.
Understanding the mechanism of action of a psychotropic
drug comprises the knowledge of a long chain of events
initiated by the recognition of its specific receptor
molecule in the central nervous system (CNS) by the drug.
Binding of the drug may either 'activate' the receptor
(i.e., alter its conformation in such a way that it will
induce further changes in adjacent structures) or
'inactivate' the receptor (i.e., alter its conformation in
such a way that it cannot be activated by other endogenous
or exogenous molecules that are otherwise capable of
activating it). The activated receptor induces, and the
inactivated receptor prevents, changes in other subcellular
elements of the target cell which regulate its
4characteristic activity (e.g., ionophores, enzymes). The
altered activity of target cells modifies the interaction
of neuron populations in one or more areas of the CNS and
results directly in somatic drug effects, and, in an
essentially unknown way, in psychotropic effects.
Benzodiazepine Receptors
Perhaps the most significant advance made in
understanding the molecular basis of BDZ action was the
simultaneous discoveries in 1977 by Squires and Braestrup,
and by Mohler and Okada of a specific receptor site for
these compounds in brain tissue. In these classic studies,
it was demonstrated that tritiated diazepam binds to brain
membranes with high affinity. This parameter refers to the
attraction of the drug for its receptor and is usually
expressed as the dissociation constant (Kd; the drug
concentration at which 50 percent of the receptors are
occupied; the lower the Kd value, the greater the
3
affinity). For H-diazepam, the Kd value is extremely low
(2.6-3.6 nM) compared to its affinity for serum albumin (10
uM) (Mohler and Okada, 1977). Binding was further characte-
rized as stereospecif ic
,
reversible, and saturable, with
maximal binding (18 pmol per g original tissue) occurring
5at a concentration of 44 nM (Squires and Braestrup, 1977).
Another characteristic feature of brain BDZ receptors
3
is their specificity. The H-diazepam binding site was
highly selective for BDZs, with 21 clinically active BDZs
3
displacing H-diazepam binding with IC50 values in the
-7
range of 3 X 10 M (Squires and Braestrup, 1977). IC50
refers to the concentration causing 50 percent inhibition
3
of specific H-diazepam binding. There was a high degree
of correlation between the ability of 26 BDZs to displace
3
H-diazepam binding in brain and their activity in a number
of predictive behavioral tests including anticonf li ct
,
muscle relaxant, and anticonvulsant tests (Braestrup and
Squires, 1978). In marked contrast to the situation using
pharmacologically active BDZs, clinically inactive BDZs
and more than 200 non-BDZ compounds (representing 22
distinct pharmacological classes, as well as 14 presumed
CNS neurotransmitters, and more than 100 peptides)
exhibited low affinity (Ki > 0.1 mM) for 3H-diazepam
binding sites (Squires and Braestrup, 1977; Braestrup and
Squires, 1977; Bosman et al
. ,
1977). Taken together, these
findings strongly indicate that the pharmacological and
clinical effects of the BDZs in vivo are mediated through
these central BDZ binding sites.
BDZ receptors are widely and unevenly distributed
6within the CNS, with very high concentrations identified in
frontal and occipital cortex, hippocampus, and cerebellar
cortex. Intermediate densities were found in the corpus
striatum, globus pallidus, hypothalamus, and retina, while
lowest binding occurred in corpus callosum, pons-medulla,
and spinal cord (Braestrup and Squires, 1977; Mohler and
Okada, 1977; Mackerer et al .
, 1 978 ; Speth et al
.
, 1 978).
3
Subcellular distribution studies revealed that H-diazepam
binding was mainly localized in the synaptic membrane
fraction (Mohler and Okada, 1977; Mackerer et al
. ,
1978).
Studies in 'nervous' mutant mice (Lippa et al
. , 1979),
kainic acid lesioned rats (Sperk et al., 1979), and humans
with Huntington's disease (Reisine et al., 1979) have
further confirmed that BDZ receptors are located on
neuronal structures. Conflicting reports, however, exist
concerning the identification of BDZ receptors on glial
cells as well (Braestrup et al
. ,
1978; Henn and Henke,
1978 ; Dudai et al. , 1 979) .
High-affinity BDZ binding has also been identified in
a number of peripheral tissues including kidney, liver, and
lung (Braestrup and Squires, 1978), muscle (Williamson et
al
. ,
1978), peritoneal mast cells (Taniguchi et al., 1980),
blood platelets (Wang et al., 1980), pineal gland (Weissman
et al
. ,
1983), anterior pituitary gland (Schoemaker et al .
,
71983), adrenal cortex (Benavides et al
. , 1983), and most
recently in brown adipose tissue (Hirsch, 1984).
Peripheral BDZ binding sites are pharmacologically distinct
from the previously mentioned brain binding sites in that
peripheral receptors show a high affinity for the
clinically inactive BDZ Ro 5-4864 ( chlordiazepam, differing
from diazepam by only a single p-chloro substitution), and
a low affinity for the clinically potent BDZ clonazepam.
Exactly the opposite holds true for brain-type BDZ
receptors. The nonneuronal sites do not show binding
regulation by GABA or by any other agents described below
which affect the neuronal BDZ binding sites (Tallman,
1 980 ) .
With the development of tritiated Ro 5-4864,
peripheral- type BDZ receptors were recently identified in
brain (Marangos et al . , 1 982 ; Schoemaker et al
.
, 1 983).
The highest concentration was measured in olfactory bulb,
intermediate concentrations were found in hypothalamus,
cerebellum, and brainstem, and the lowest concentrations
were observed in cortex, striatum, and hippocampus. A
comparison of the central- and peripheral- type BDZ receptor
3
density shows that H-Ro 5-4864 binding density amounts to
about 10-15 percent of that of the central-type receptor in
the cortex and hippocampus, and 60 percent in the olfactory
8bulb and cerebellum. The brainstem and pituitary
respectively contain 1.5 and 30 times as many peripheral-
type as central-type recognition sites (Schoemaker et al .
,
1983). An examination of subcellular distribution revealed
that these peripheral- type BDZ receptors were mainly
located in the nuclear fraction. Thus, the regional and
subcellular distribution of peripheral- type BDZ receptors
in brain is quite different from that of classical central-
type BDZ receptors. Although some evidence has implicated
peripheral-type BDZ receptors in the regulation of
prolactin release (Grandison, 1981) and in experimentally-
induced hypertension (Regan et al
. , 1981), the physio-
logical significance of this unique type among BDZ
receptors remains to be firmly established.
Benzodiazepine - GABA Interactions
Communication between nerve cells is made possible by
the release of neurotransmitters, at least 20 of which have
already been identified. Hence, drugs that modify behavior
have invariably also been found to modify the biosynthesis,
release, reuptake, or metabolism of neurotransmitters.
Early studies on the interactions between the BDZs and
brain neurotransmitters demonstrated that BDZs decreased
9the turnover rates of acetylcholine, serotonin, dopamine,
and norepinephrine within the same dose range that produces
their therapeutic actions (for reviews, see Feldman and
Quenzer, 1984; Costa and Greengard, 1975). This effect
occurred with all neurotransmitters studied, and the
direction of change was identical in all cases, suggesting
that the decreased turnover of neurotransmitters might not
be a primary effect; rather these alterations might be
occurring secondary to a more general CNS depression.
Therefore, it is not surprising that more recent
investigations have focused on BDZ interactions with the
inhibitory neurotransmitters glycine and gamma aminobutyric
acid (GABA). In one of the original neurotransmitter
receptor binding studies, Snyder and Enna (1975)
demonstrated that BDZs could inhibit tritiated strychnine
binding to glycine receptors in rat spinal cord membrane
prepartions with relative potencies that were highly
correlated with their relative potencies as anxiolytics
and muscle relaxants. However, the theory that BDZs exert
their therapeutic effects by directly activating glycine
receptors soon became untenable when it was found that 1
)
BDZs failed to enhance postsynaptic inhibition in the
spinal cord, a glycine mediated phenomenon (Curtis et al .
,
1976), and 2) the potency of BDZs to inhibit glycine
10
receptors soon became untenable when it was found that 1)
BDZs failed to enhance postsynaptic inhibition in the
spinal cord, a glycine mediated phenomenon (Curtis et al
.
,
1976), and 2) the potency of BDZs to inhibit glycine
receptor binding was 1000 fold lower than the affinity of
BDZs to bind to their own receptors.
In trying to assign a particular neurotransmitter
system as the primary site of action of BDZs, overwhelming
evidence would seem to implicate GABA for such a role. As
is true for other neurotransmitter systems, BDZs decrease
GABA turnover in the brain (Bertilson et al., 1977).
Unlike the case with other systems, however, a wealth of
electrophysiological and biochemical data identified
GABAergic synapses as the primary site of action of the
BDZs (for reviews, see Gallager, 1983; Tallman et al
.
,
1980; Gallager et al
. , 1980; Olsen, 1981).
Electrophysiological studies
Using electrophysiological techniques to measure
spontaneous electrical activity, evoked responses, or
single-cell neuronal activity, several investigators have
concluded that at least some of the actions of BDZs result
from a specific interaction with GABA. Schmidt et al.
(1967) were the first to observe the potentiation by
11
diazepam of presynaptic inhibition in the oat spinal cord,
and they suggested that this might contribute to the
central muscle relaxant effect of this drug; postsynaptic
inhibition in the spinal cord was found to be unaffected by
diazepam. The significance of these findings for the
mechanism of action of BDZs was not recognized for several
years, first, because at that time the phenomenon of
presynaptic inhibition was still a matter of debate among
physiologists and, second, because the transmitter
mediating this type of inhibition was not known.
When in the early seventies increasing evidence
indicated the role of GABA in the axo-axonal synapses that
mediate presynaptic inhibition of primary afferent endings,
Pole et al. (1974) reinvestigated the effects of diazepam
on the cat spinal cord. Diazepam increased the amplitude
and duration of the dorsal root potential, which is the
expression of the synaptically-induced depolarization of
primary afferent endings, and enhanced the presynaptic
inhibition of the monosynaptic excitation of spinal
motoneurons (ventral root reflex). GABA antagonists such
as picrotoxin and bicuculline antagonized this diazepam
action. After depletion of endogenous GABA by the
synthesis inhibitor thiosemicarbazide, presynaptic
inhibition was abolished and could no longer be restored by
12
BDZs. By itself diazepam did not produce a depolarization
of primary afferents, which means that BDZs have no GABA-
mimetic action.
In order to establish whether this BDZ action was
unique to presynaptic inhibition in the spinal cord, or
could be extended to all GABA-mediated neurotransmission,
Pole and Haefely (1976) studied the effect of diazepam on
dorsal column nuclei, a site where GABA has been shown to
mediate both presynaptic and postsynaptic inhibition.
Diazepam potentiated both types of synaptic inhibition
(recorded in the cuneate nucleus). As already seen in the
spinal cord, BDZs and GABA antagonists were mutually
antagonistic in their effects on synaptic inhibition, and
again the depletion of endogenous GABA by thiosemicarbazide
abolished any effect of diazepam. The results in the
cuneate nucleus, therefore, strongly suggested that these
drugs might similarly affect all GABAergic synapses in the
CNS, and for the first time it was considered possible that
the whole pharmacology of the BDZs could be explained by a
facilitation of post synaptic GABA receptors.
Further evidence for this notion was provided by Costa
and his coworkers using an elegant GABAergic system in the
cerebellum. The cerebellum consists of two parts: the
cerebellar nuclei where connections to the various parts of
13
the CNS coordinate muscle movements, and the cerebellar
cortex which exerts an inhibitory influence on the
cerebellar nuclei through the release of GABA from Purkinje
cell axons. The activity of Purkinje cells is regulated by
two excitatory inputs to the cerebellar cortex (the
climbing and mossy fibers), and by a neuronal network
within the cerebellar cortex which inhibits the activity of
Purkinje cells through the release of GABA from inter-
neurons
.
The net activity of Purkinje cells, the sole output of
the cerebellar cortex, appears to be related to their
content of cyclic GMP which increases or decreases in
relation to the changes in the excitatory and inhibitory
input to the Purkinje cells (Costa et al., 1975). When
GABA receptors located on Purkinje cells are activated, the
cyclic GMP content of these cells decreases; when they are
inhibited the cyclic GMP content increases. Thus, the
decrease of the cyclic GMP content of cerebellar cortex is
a good index of the state of activation of GABA receptors.
Biggio et al. (1977) showed that diazepam, similar to the
direct GABA receptor agonist muscimol, lowers the cyclic
GMP content of cerebellum by activating GABA receptors.
Furthermore, diazepam antagonized the increase in cerebel-
lar cyclic GMP elicited by isoniazid, an inhibitor of GABA
14
synthesis. Diazepam is active when the cerebellar GAB
A
content is decreased by up to about 30 percent. However,
when this decrease is greater than 30 percent, diazepam
cannot counteract the increase in cerebellar cyclic GMP
elicited by isoniazid (Guidotti, 1978). In contrast,
muscimol completely counteracts this action of isoniazid
even when the cerebellar content of GABA is reduced by more
than 30 percent. This suggests that the action of diazepam
on cerebellar GABA receptors depends on the amount of GABA
that is stored in the synapses that impinge on Purkinje
cells. This finding implies that either GABA is released
by diazepam or that diazepam increases the affinity for
GABA of the postsynaptic GABA receptors. The former of
these two possibilities was quickly ruled out when it was
demonstrated that diazepam had no effect on either the in
vitro (MacDonald et al
. ,
1978) or the in vivo (Geller et
al., 1978) release of GABA. Thus, from electrophysio-
logical studies, alterations in postsynaptic responses to
GABA appeared the most likely mechanism by which BDZs
facilitate GABAergic neurotransmission.
Receptor binding studies
Although electrophysiological experiments had
indicated an interaction between BDZs and GABA, the first
15
direct demonstration of the nature of this interaction came
soon after the discovery of the brain BDZ receptor in 1977.
The application of sensitive recep tor-ligand binding assays
with compounds of high specific activity has made possible
the investigation of postsynaptic mechanisms at the
subcellular level. it was originally thought that the BDZ
binding site in mammalian brain did not have any relation-
ship to known transmitters (Braestrup et al., 1977).
Subsequent studies using lower ligand concentrations,
however, revealed an intimate interaction between BDZs and
GABA (for reviews, see Ticku, 1983, and Guidotti et al
.
,
1983)
.
The development of an in vitro biochemical assay for
studying brain GABA receptors made it possible to examine
the influence of various drugs (notably BDZs, barbiturates,
and convulsants) on this site (Enna and Snyder, 1975). For
this assay, membranes prepared from brain tissues are
3
incubated with H-GABA, and under the appropriate
conditions, the number of GABA receptors in the tissue can
be quantified by measuring the amount of isotope bound.
When added to the incubation mixture, drugs capable of
interacting with this receptor site will inhibit the
3 3
binding of H-GABA. The potency of a drug to inhibit H-
GABA binding may be taken as an index of its potency to
16
activate, or inhibit, the receptor site in vivo.
A major breakthrough in the understanding of the
intimate interaction that exists between BDZs and GABA
receptors occurred following an attempt to solubilize the
GABA receptor (Enna and Snyder, 1975). Usually the
recognition sites for transmitters are solubilized when the
membranes are treated with the nonionic detergent Triton X-
100. This procedure disrupts the membrane and washes away
any water-soluble proteins that might be adhering to the
lipid membrane. Therefore, such a treatment reduces the
number of receptors (Bmax) for these transmitters, but
leaves their receptor affinity (Kd) either unchanged or
slightly decreased. In contrast to the usual situation,
when brain membranes were incubated with a low concentra-
3
tion of Triton X-100, the amount of H-GABA bound to
membranes increased dramatically. Scatchard analysis
indicated that both the Bmax and the Kd were significantly
increased in Triton- treated tissue. In fact, treatment
with Triton X-100 revealed the presence of a second GABA
receptor site with an affinity for the neurotransmitter
some ten times greater than the site observed in tissue not
treated with the detergent (Enna and Snyder, 1977). This
finding was interpreted as indicating that, on or near the
GABA receptor recognition site, there is a substance (or
17
substances) that normally masks the higher affinity site.
Removal of this substance leads to a more sensitive
receptor since a higher affinity site will be activated by
a lower concentration of ligand. Guidotti et al . (1979)
found that, if membranes are incubated with BDZs rather
than Triton, the same phenomenon occurs. Thus, without BDZ
treatment, only a single, low affinity (210 nM) GABA
receptor binding site can be detected in brain membranes.
If the tissue is preincubated with increasing concentra-
tions of diazepam, however, a second, higher affinity site
becomes evidenced. At maximal concentrations of diazepam
this high affinity site has approximately ten-fold greater
attraction for GABA than the low affinity component. These
authors reported similar effects with other BDZs such as
nitrazepam, f luni tr azepam , and clonazepam.
To verify the possibility that untreated GABA
receptors contained an endogenous inhibitor of the high-
affinity GABA receptor, Costa et al . (1978) prepared two
types of crude synaptic membranes from rat cerebral and
cerebellar cortex. Their Type B membranes were freshly
prepared and showed the characteristic low affinity GABA
binding. Type A membranes were obtained by further
treating Type B membranes with Triton X-100, such that they
demonstrated both high and low affinity GABA binding. When
18
aliquots of supernatant buffer obtained by centrifuging a
suspension of Type B membranes were added to Type A
3
membranes, high affinity H-GABA binding to Type A
membranes was inhibited. A 15,000 dalton protein was
identified following 500-fold purification of the Type B
supernatant. Addition of 0.33 ug of this protein to Type A
membranes completely abolished high affinity GABA binding.
In other words, there appears to be an endogenous protein
inhibitor of high affinity GABA binding that can be removed
following treatment with Triton X-100. When extracted from
non-treated membranes (Type B) and added to Triton- treated
membranes with unmasked high affinity GABA receptors (Type
A), the endogenous inhibitor remasks these high affinity
GABA recognition sites. This endogenous inhibitor was
termed GABA-modulin.
These authors further demonstrated that diazepam can
reverse the effect of GABA-modulin on Type A membranes.
3
Similarly, GABA-modulin was shown to inhibit H-diazepam
binding to Type A membranes. From these results it was
proposed that BDZs compete with GABA-modulin for the high
affinity GABA recognition site. These findings were quite
provocative, and represented a breakthrough in understan-
ding the mechanism of action of BDZs. It was surmised that
BDZ administration results in the displacement of GABA-
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modulin, revealing a higher affinity GABA receptor site,
making the postsynaptic membrane more sensitive to activa-
tion by GABA. In this way, BDZs can potentiate GABAergic
activity, which may in turn influence the activity of other
neurotransmitter systems (Guidotti et al .
, 1 979).
The effects of various drugs on labelled BDZ binding
in brain were being simultaneously investigated. Using
cortical membranes, the in vitro addition of GABA or GABA
3
agonists such as muscimol enhanced the binding of H-
diazepam (Tallman et al
. , 1979; Williams and Risley, 1979).
Other amino acid transmitters including glycine, glutamate,
3
and aspartate did not affect H-diazepam binding (Tallman
et al., 1978), indicating that this effect was specific to
GABA. It was further established that the enhanced
binding of BDZs observed after the addition of GABA was due
to an increase in the affinity of the BDZ receptor for its
ligand without altering receptor number (Tallman et al.,
1978). In vivo pretreatment of animals with the GABA
catabolic inhibitor amino oxyacetic acid (AOAA) resulted in
3
an increase in specific H-diazepam binding. Pronounced
increases in BDZ binding were also observed after pretreat-
ment of animals with the GABA analogs muscimol, baclofen,
and gamma-buty rol actone (Gallager et al., 1978). The
enhancement of BDZ binding by either GABA or muscimol was
20
blocked by the in vitro addition of the GABA antagonist
bicuculline (Tallman et al
. , 1978) . Taken together with
results from GABA receptor binding studies, it is apparent
that BDZ binding can be altered by GABA and GABAergic
compounds, and similarly GABA binding can be modulated by
BDZs.
Soon after the GABAergic modulation of BDZ binding was
described, it became clear that a number of other compounds
were capable of enhancing the affinity of the BDZ receptor.
Prominent among these were several physiologically relevant
anions, including chloride, iodide, and thiocyanate (Costa
et al
. , 1979). These results were not surprising, however,
since it was already well established that the GABA
receptor is closely linked with a chloride ion channel.
When a GABA molecule is associated with its receptor site,
chloride gates (ionophores) open up, allowing chloride ions
to freely diffuse across the cell membrane according to the
concentration gradient. The consequence of such an
association, whether hyperpolarization of postsynaptic
membranes or depolarization of presynaptic membranes, is
always reduced effectiveness of sodium excitatory
conductance (inhibition). Thus, the above data are consis-
tent with the notion that the GABA/BDZ receptor complex is
associated with a chloride ionophore.
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The fourth and last component of this putative supra-
molecular GABA complex is a pier otoxin/barbi turate binding
3
site characterized by high affinity H-dihy dr opicrotoxin
(DHP) binding. An analogue of picrotoxin, DHP is also a
potent convulsant and GABA antagonist. Although neither
GABA nor BDZs bind to the site labelled by DHP, this site
appears to be an important locus of action for a number of
centrally active depressant and convulsant drugs (Olsen,
1981).
The binding of DHP is inhibited in a stereospecif ic
manner by barbiturates, particularly those with anesthetic
and anticonvulsant properties (Willow and Johnston, 1981).
DHP binding is similarly inhibited by dipheny lhy dantoin and
ethanol (Ticku and Davis, 1981), as well as by etazolate
and cartazolate, several new non-BDZ anxiolytic compounds
of the pyrazolopyridine class (Williams and Risley, 1979).
Evidence exists that the pharmacological effects of
barbiturates, ethanol, di pheny lhy dantoi n , and the pyrazolo-
pyridines may be mediated through GABAergic mechanisms,
since each of these drugs increases the number of
detectable GABA receptors and potentiates the GABAergic
modulation of BDZ binding site affinity. The ability of
these agents to enhance GABA binding was blocked by either
picrotoxin or DHP (Supavilai and Karobath, 1980; Olsen,
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1981; Ticku, 1983; Greenberg et al
. ,
1 9 84). The in vivo
significance of this picrotoxin/barbiturate recognition
site remains to be determined.
Thus, it is currently believed that BDZs,
anticonvulsant and anesthetic barbiturates, alcohol,
diphenylhydantoin, certain convulsants, and selected non-
BDZ anxiolytics exert at least some of their pharmacologi-
cal effects through an interaction at a four-site
supramolecular complex. Binding sites for DHP, GABA, and
BDZs show a similar subcellular and brain regional
distribution (Ticku et al
. , 1978), further supporting such
a possibility. This molecular complex is comprised of a
GABA recognition site, a BDZ and GABA-modulin recognition
site, a picrotoxin and barbiturate recognition site, and an
associated chloride ionophore. Although it is not fully
clear how interactions at these sites mediate one or
another of the pharmacological actions ascribed to these
drugs, a number of hypothetical models of this receptor
complex have been advanced in an effort to better integrate
existing data (Feldman and Quenzer, 1984; Guidotti et al
.
,
1983; Gallager et al., 1980). According to these
proposals, the GABA recognition site is believed to be
functionally linked to the chloride ionophore, and a
conformational change resulting from an interaction between
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GABA and its receptor is proposed to regulate the opening
of this ion channel. BDZs and G AB A-modulin compete for a
satellite receptor attached to the GABA receptor. Neither
of these substances directly activates the chloride
ionophore; rather they are believed either to facilitate
(BDZs) or to hinder ( GABA-modulin) the activation of the
chloride ionophore by GABA. The final ligand binding site
is shared by picrotoxin and barbiturates, and is believed
to be closely linked to the chloride conductance channel at
a site distal from the GABA receptor. The final transducer
of this 250- 350,000 dalton supr amol ecular complex is the
chloride ion, and this ion is regulated by what appears a
rather complicated set of interactions between endogenous
and exogenous chemicals at these various recognition sites.
Endogenous Benzodiazepine Receptor Ligands
By analogy to the search for and the eventual identi-
fication of naturally occurring opioid compounds (enkepha-
lins, endorphins, dynorphins), the discovery of a specific
BDZ receptor in brain has prompted the quest for a similar
endogenous ligand of the BDZ receptor. Such a ligand would
be expected to bind with high affinity at physiological
concentrations to BDZ receptors and would also be expected
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to display "BDZ-like" pharmacological actions in vivo.
Using receptor binding methodology to assay tissue extracts
for the ability to inhibit labelled BDZ binding, a fair
number of putative endogenous ligands for the BDZ receptor
have been identified (for reviews, see Guidotti et al.,
1983; Hamon and Soubrie, 1983). The ultimate goal in
seeking endogenous ligands for drug receptors is a better
understanding of the natural mechanisms underlying the drug
mediated physiological effects. For example, endogenous
"BDZ-like" substances would be expected to have anxiolytic,
anticonvulsant, and muscle relaxant effects. Identifica-
tion of these natural compounds and characterization of
their interaction with the BDZ receptor should, therefore,
provide insights that concern the mechanisms governing
these neurophy siological processes.
GABA-modulin
The first compound to be isolated from brain that
3
competitively inhibited H-diazepam binding from cortical
membranes was the aforementioned GABA-modulin. This water
soluble, basic, heat stable protein having a 15,000 dalton
molecular weight was first reported to inhibit GABA
binding, and also to prevent the increase in BDZ binding
produced by GABA (Guidotti et al .
,
1 978). These results
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led Guidotti et al
. ( 1979) to propose that GABA.modulin
might be the endogenous ligand for the BDZ recognition
site. However, GABA-modulin was extremely difficult to
purify due to its rapid degradation of GABA-modulin by
proteolytic enzymes, and secondly because of problems
encountered removing GABA itself from the crude extract.
For this reason, GABA-modulin could not be fully
characterized, and sufficient quantities for pharmaco-
logical and physiological testing were not obtainable.
Thus the "BDZ-like" effects of this substance could not be
assessed
.
However, Guidotti et al . (1983) eventually succeeded
in isolating and characterizing GABA-modulin. It has now
been established that purified GABA-modulin contains 126-
131 amino acids (none of which is GABA) and has a
molecular weight of 16,500 daltons. Purified GABA-modulin
3
blocked high affinity H-GABA binding to synaptic
membranes, and prevented G ABA-stimulated diazepam binding
(Guidotti et al., 1982). The presence of a large number of
serine and threonine amino acid residues that are preferen-
tial phosphate acceptors, led Wise, Guidotti, and Costa
(1983) to investigate whether GABA-modulin could be
phosphory lated and whether phosphorylation would modify the
biological activity of this protein. Results showed that
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GABA-modulin could be phosphorylated by both a cAMP-
dependent protein kinase and various calcium- and
calmodulin-dependent kinases. The cAMP-dependent phosphor-
ylation, but not that catalysed by calcium-dependent
kinases, abolished the capacity of GABA-modulin to mask the
high affinity binding sites for GABA in brain membranes.
It was further shown that the enzymes necessary for
phosphorylation are present in vivo in close proximity to
the endogenous GABA-modulin in synaptic membranes.
Based on these findings, Guidotti et al . (1983) and
Wise et al
. (1983) now postulate that GABA-modulin
functions in GABA receptors as a coupling protein.
In their view, GABA-modulin is not normally phosphorylated.
When the BDZ recognition site is occupied by an anxiolytic
BDZ the protein is phosphorylated and the high affinity
recognition sites of the GABA receptor are unmasked. Thus,
GABA-modulin is no longer envisioned as an endogenous
ligand for the BDZ receptor; rather this protein is
considered a coupling mechanism by which BDZ recognition
sites modify GABA receptor mechanisms.
Purines
Using an acetone extraction procedure, Marangos et al
.
(1978) isolated two non-pep tidergic fractions from bovine
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brain that inhibited H-diazepam binding. Further analysis
identified these two fractions as the purines inosine and
hypoxanthine. The affinity of inosine and hypoxanthine for
the BDZ receptor was approximately 20,000 times lower than
that of the BDZs, with the Ki values for inosine and
hypoxanthine 836 and 982 uM respectively. These compounds
did not bind to opiate, beta-adrenergic, muscarinic
cholinergic, or GABA receptors, indicating that purinergic
binding is specific for the BDZ receptor (Osano and
Spector, 1979). Although inosine and hypoxanthine
possessed weak anticonvulsant effects, the concentrations
required were extremely high (150 ug i.e. v. and 1 g/kg
i.p.) (Marangos et al
. ,
1981).
When viewed in the context of other receptor-ligand
systems (with binding potencies in the nanomolar range),
the extremely low potency of the purines as inhibitors of
diazepam binding seems to preclude their being physio-
logical modulators of BDZ receptors in vivo. However, it
was argued by Marangos et al . (1980) that following
electrical or chemical depolarization of brain tissue, the
concentrations of inosine and hypoxanthine rise dramatic-
ally. As further support for their position, they cite the
demonstration by Lippa et al . (1979) that only 15-20
percent BDZ receptor occupancy is necessary either to
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produce conflict avoidance in the rat, or to fully antago-
nize convulsions in mice produced by pentylenetetrazol.
These arguments notwithstanding, with the concentration of
these compounds in brain estimated to be between 20-60 uM
(and Ki values for diazepam inhibition close to 1 mM) , it
seems improbable that BDZ receptors could be occupied by
these compounds at concentrations sufficient to produce any
meaningful effects. As suggested by Karobath (1983), with
binding inhibition evidenced only at concentrations close
to their limits of solubility in aqueous solutions, in
order for the purines still to be considered as endogenous
ligands for the BDZ recognition site, it would first be
necessary to propose some alternative hypothesis such as
compartmentalization with high concentrations at GABAergic
synapses
.
Nicotinamide
Using an extraction procedure similar to that employed
for inosine and hypoxanthine , Mohler et al. (1979) isolated
nicotinamide from bovine and rat brain. This naturally
3
occurring compound similarly inhibited H-diazepam binding.
The IC
, however, was extremely high (3. 9 mM) . Although
50
nicotinamide displayed "BDZ-like" properties as a muscle
relaxant and anticonvulsant, and showed nBDZ-like n effects
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in the rat conflict test, the extremely low concentration
of nicotinamide in brain (0.1 mM) (Mohler et al .
, 1979) is
difficult to reconcile with a physiologically significant
action. Therefore, for reasons similar to those already
expressed for the purines, nicotinamide can probably be
excluded from consideration as an in vivo BDZ ligand.
Indol es
Squires et al
. (1979) reported that tryptophan
displaces H-diazepam binding with a potency comparable to
that of the purines and nicotinamide. This prompted
Marangos et al. (1981) to investigate the effects of a
dozen tryptophan derivatives on diazepam binding. Of those
compounds tested, melatonin and its brain metabolite N-
ace tyl-5-methoxy kynurenamine (AMK) were found to be the
most potent, with Ki values of 415 and 49 uM respectively.
Therefore, melatonin and AMK were two- and twenty-fold more
potent than the purines or tryptophan as inhibitors of BDZ
binding. However, the concentration of melatonin is only
20 uM in pineal and 1.5 uM in hypothalamus (Marangos et
al., 1981), effectively eliminating melatonin from
contention as the endogenous BDZ-like substance in brain.
It is of interest to note, however, that of all the
putative endogenous BDZ ligands tested to date (including
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AMK and the purines), only melatonin was a more potent
inhibitor of peripheral- type BDZ binding than of central-
type BDZ binding. Whether melatonin serves as a natural
ligand for the peripheral- type BDZ receptor, however,
remains to be determined. Since the concentrations of AMK
in pineal and in brain have not been determined, judgement
concerning the physiological relevance of this compound
cannot be assessed.
Miscellaneous compounds
Additional low molecular weight compounds that
displace BDZ binding have been isolated from brain and
urine, but have not been identified (Clow et al., 1983;
Massotti et al
.
,
1981; Colello et al
.
, 1 978). Before these
substances can be considered as possible endogenous "BDZ-
like" compounds, it first must be demonstrated that they
exist in brain, and secondly it must be shown that they
were not formed during the extraction procedure. Such
caution is merited in light of the recent demonstration
that the putative endogenous BDZ-ligand isolated from rat,
bovine, and human brain by Braestrup et al . (1980), beta-
carbol ine-3-carboxylate ethyl ester, was indeed an
artifact of their extraction procedure (Karobath, 1983).
•
Although still in its early stages, the evidence
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summarized above indicates that endogenous "BDZ-like"
compounds do exist in the CNS. However, in order that a
putative endogenous ligand for the BDZ receptor be
established as a true neurotransmitter or neuromodulator,
the following criteria have to be satisfied: 1) The
compound should competitively inhibit BDZ binding and be
present in vivo at concentrations that are consistent with
the binding potency. 2) It should mimic the neurophysio-
logy and biochemical effects of BDZs. 3) Administration
of the compound to animals should produce "BDZ-like"
pharmacological and behavioral effects. 4) Nervous tissue
should be able to metabolize, store, and release the
compound in question. 5) The receptor binding inhibition
should be specific for BDZs. Although each of compounds
just described meet some of these criteria, the evidence to
date argues that the natural ligand for the BDZ receptor
still remains to be identified.
Exogenous Benzodiazepine Receptor Ligands
Stimulation of BDZ recognition sites by various
ligands can elicit opposite types of pharmacological
responses. The study of the pharmacological profiles of
these various ligands makes it possible to distinguish
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three classes of compounds. The first group comprises the
classical BDZs and three chemically unrelated compounds,
zopiclone (Wickstrom and Giercksky, 1980), CL 218,872
(Lippa et al., 1979), and CGS 9896 (Gee and Yamamura,
1982). Binding of this group of ligands produces the
typical BDZ profile, including anticonvulsant, muscle
relaxant, and anticonflict effects. The term agonist has
been applied to members of this group.
The second group of BDZ receptor ligands similarly
displaces BDZs from specific binding sites, yet members of
this group display a pharmacological profile opposite to
that of the BDZs. Consequently, these so called inverse
aflonists exhibit proconvul sant
,
convulsant, and anxiogenic
properties. However, in conjunction with an agonist
,
the
pharmacological effects of both compounds are attenuated
(for reviews, see Boast et al
. ,
1983; Braestrup et al
.
,
1983, 1984). So far this group is restricted to beta-
carbol ine-3-carboxy lates such as the methyl-, ethyl-, and
propyl-esters (BCCM, BCCE, and BCCP), the methylamide
(BCCMA), and 6 , 7-dimethoxy-4-ethyl-beta-carboline-3-
carboxylate (DMCM).
The third class of exogenous BDZ receptor ligands is
comprised of compounds that display no pharmacological
actions of their own, except at very high doses, yet
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interaction with this recognition site.
MK-80
1
A dibenzocycloheptenimine derivative MK-801 (Merck) is
a potent anxiolytic and anticonvulsant in rats
(Clineschmidt et al., 1982), without profound sedative and
muscle relaxant effects (Goldberg et al
. , 1983). MK-801
3 3
had no effects on H-diazepam or H-f luni traz epam binding
up to 1 uM (Goldberg et al
. ,
1983).
CL 218.872
It was originally believed that there existed in brain
only a single homogeneous class of central-type BDZ binding
sites. In both rat and human, Scatchard analysis of
equilibrium binding yielded straight lines with no tendency
to resolve into more than one component (Braestrup and
Squires, 1977). Hill analysis of displacement curves for
15 BDZs yielded Hill coefficients near unity (Speth et al
.
,
1978). Such coefficients are generally interpreted to
indicate a single binding site as well as the lack of
cooperati vi ty between binding sites. Further support for
the presence of a single class of central-type BDZ binding
sites was provided by the demonstration that thermal
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inactivation of binding sites (preincubation of membrane
o
preparations at 60 C in Tris HC1 buffer) was monophasic
( Squires et al
. , 1979).
However, more recent evidence, together with a
reevaluation of some existing data, now indicates that
there exist two distinct types (or subtypes) among central-
type BDZ receptors. For example, while the ability of BDZs
3
to displace H-diazepam binding was highly correlated with
their anticonflict (Lippa et al., 1978) and anticonvulsant
( pentylenetetrazol-induced; Paul et al
.
, 1 979) potencies,
3
only 15-20 percent of H-diazepam binding had to be
displaced to observe these effects. When heat inactivation
of labeled BDZ binding sites is carried out in sodium
phosphate buffer rather than Tris HC1, binding sites
disappear in a biphasic manner with half-lives of
o
approximately 10 and 70 minutes at 60 C (Squires et al .
,
1979). In addition, approximately H0 percent of the total
3
number of H-f luni tr az epam binding sites were found to be
G AB A-independent (not protected by GABA or muscimol against
thermal inactivation ) (Klepner et al . , 1979). Consistent
with the latter finding, about 50 percent of the BDZ
receptors are not coupled to chloride ionophores (Klepner
et al
.
, 1 979) .
Perhaps the single most significant advance in the
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concept of BDZ receptor heterogeneity was the development
of the triazolopyridazines (TPZs). TPZs were the first
non-BDZ compounds found that bind to central-type BDZ
receptors, both in vivo and in vitro, with a potency
comparable to that of the BDZs (Squires et al., 1979).
TPZs, however, have an extremely low affinity for
peripheral-type BDZ receptors, both in brain and in kidney
(Marangos et al
. ,
1981). This uniq ue class of compounds
interacts with central-type BDZ receptors with Hill
coefficients significantly less than unity (0.5 - 0.7;
Squires et al
. , 1 979), indicating the existence of more
than one BDZ receptor site. Hofstee analysis of the
displacement of labeled diazepam binding by TPZs yielded
curvilinear plots which could be resolved into two
components (Lippa et al
. , 1979), again indicating the
existence of more than one receptor type. The high-
affinity sites for TPZs were designated as Type I
receptors, while the low-affinity sites were designated as
Type II receptors. Squires et al . (1979) and Klepner et
al. (1979) further characterized the Type I receptor as
independent of GABA receptors and chloride ionophores.
Type II receptors, on the other hand, were coupled to GABA
receptors and/or chloride ionophores.
Unlike the situation using BDZs, the potency of CL
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218,872 to displace H-diazepam binding, as well as its
calculated Hill coefficient, varied as a function of brain
region (Morelli et al
.
, 1981; Klepner et al
.
, 1 979). CL
218,872 was found to be most potent in cerebellum, less
potent in thalamus, frontal cortex, globus pallidus, and
substantia nigra, and least potent in putamen, hippocampus,
and hypothalamus (Morelli et al
. ,
1981). Hofstee analysis
revealed that these differences were not due to any
differences in the affinity of CL 218,872 for the two
receptor types, but rather to differences in the relative
density of Type I and Type II BDZ receptors in each brain
region (Lippa et al
. ,
1980). They reported that approxim-
ately 90 percent of the BDZ binding sites in cerebellum are
Type I receptors, whereas only 40 percent of the BDZ
binding sites in hippocampus are Type I receptors.
These results confirmed previous reports of multiple
types among central-type BDZ receptors and firmly
demonstrated the existence of two pharmacologically
distinct central-type BDZ binding sites. Both BDZs and
TPZs have a high affinity for Type I receptors, whereas
only BDZs have a high affinity for Type II receptors.
Equally important, however, was the demonstration that the
prototypical TPZ, CL 218,872, similar to the BDZs,
increased punished responding in a conflict situation and
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protected against pentylenetetrazol- induced convulsions
(Lippa et al., 1979), pharmacological properties which are
highly predictive of anxiolytic activity. This finding
further strengthened the notion that antianxiety activity
and affinity to the BDZ receptor are closely related.
However, unlike the BDZs, CL 218,872 was purportedly devoid
(at anxiolytic doses) of depressant side effects associated
with the BDZs (i.e., sedation, ataxia) and was very weak in
its ability to inhibit the convulsions produced by bicucul-
line, isoniazid, or strychnine (Lippa et al
. , 1979).
In addition to further confirming the existence of
heterogeneous forms of BDZ receptors, the TPZs present a
unique opportunity to further clarify the molecular basis
by which BDZs induce their various behavioral and
physiological actions. As such, the TPZs may represent a
new probe for selectively investigating the neural
mechanisms that underlie anxiety and its alleviation.
Specifically, it may be possible to infer that any similar
actions produced by both BDZs and TPZs (at appropriate
doses) result from activation of Type I BDZ receptors.
Alternatively, any actions produced by BDZs, but not by
TPZs, may be attributable to Type II BDZ receptor
stimulation.
Furthermore, since the TPZs may ultimately be of great
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s
value in the clinical treatment of anxiety disorders
due to their lack of depressant side effects, it i
important to learn more about the behavioral, neurochem-
ical, and endocrine actions of these compounds. Indeed
pharmacologists are always seeking drugs with enhanced
specificity. It is therefore important to learn more about
the similarities and differences between the actions of
BDZs and this novel class of compounds, so as to better
assess their potential for clinical application.
Therefore, the present series of investigations
examined the ability of the prototypical TPZ, CL 218,872,
as compared to the BDZ , chl or di az epoxi de , to:
1) induce a discriminative stimulus complex similar to
that produced by chlordiazepoxide
. The potencies at which
BDZs generalize to the discriminative cue elicited by
chlordiazepoxide correlate well with the potencies of their
therapeutic effects (Colpaert et al., 1976). For this
reason Lai and Sherman (1982) have suggested that the BDZ-
saline drug discrimination paradigm may represent an animal
test predictive of anxiolytic activity.
2) alter serotonin and catecholamine turnover rates.
It has been proposed that BDZs exert their antianxiety
effects by reduction of serotonin activity, and their
depressant effects by reduction of catecholamine
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activity (Wise et al
. ,
1972). According to this hypothesis
one might expect CL 218,872 to decrease serotonin turnover,
yet have no effect on catecholamine turnover.
3) prevent stress-induced elevations in serum cortico-
sterone. Pretreatment with BDZs or with other agents
possessing antianxiety activity, such as meprobamate or
barbiturates, has been reported to block or reduce the
elevation in circulating cortico st erone (a glucocorticoid
hormone secreted from the cortex of the adrenal glands)
produced by experimenter-induced stress. These and other
findings have led Lahti and Barsuhn (1974), and LeFur et
al. (1979) to propose that the corticosterone stress test
could be used to screen for potential antianxiety agents.
Accordingly, one might expect CL 218,872 to block stress-
induced elevations in corticosterone concentrations.
Finally, since the above behavioral, neurochemical,
and endocrine actions produced by BDZs have each been
considered either predictive of, or responsible for, the
anxiolytic potential of this class of drugs, CL 218,872
presents an opportunity either to confirm and extend or to
refute the validity of such measures as indicators of a
drugs' clinical (anxiety reducing) potential.
CHAPTER II
EXPERIMENT I
GENERALIZATION BETWEEN CHLORDI AZEPOXIDE- AND
CL 218,872-ELICITED DISCRIMINATIVE CUES
Introduction
Several approaches have been used to establish the
pharmacological identities of BDZs. One such approach has
been the use of drug discriminative paradigms. Drug
discrimination learning requires the drug to produce a
perceivable change in some aspect of the animal's internal
environment. By producing this interoceptive cue, the drug
versus saline injections can then be applied as distinct
discriminative stimuli, thus making it possible to train
animals to perform one type of behavior for reinforcement
following a drug injection and to perform a different, but
topographically similar behavior following injection of
drug vehicle
.
In the majority of drug discrimination studies, the
animal is required to either make opposite turns in a T-
maze (Overton, 1978) or opposite choices in a two-lever
test chamber (Colpaert et al., 1976). Different, but
equivalent responses have also been trained in other test
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procedures, such as the Lashley jumping stand (Brown et
al., 1968) and choices between side compartments in a
three-chambered apparatus (Schechter and Rosecrans, 1973).
The incentive for the correct response in these studies has
either been food reward or escape from shock. When acqui-
sition of such response differentiation is reliably estab-
lished, the drug is said to produce a discriminative
stimulus. At this point, stimulus generalization and
antagonism experiments can be employed in an attempt to
establish the biochemical mechanisms underlying elicitation
of the discriminative stimulus (drug cue).
The BDZs have been extensively investigated in drug
discrimination procedures. For example, chlordiazepoxide
(CDP) is able to produce a discriminative stimulus in rats
(Colpaert et al
. , 1 976; Colpaert, 1 977; Brown et al
.
, 1 968 ;
Overton, 1979). It was found that the potencies at which
other BDZs generalize to the CDP cue (ability of the test
compound to produce responding on the CDP appropriate
lever) correlate well with their ataxic and anticonvulsant
( pentylenetetrazol-induced ) effects (Colpaert et al.,
1976). Furthermore, only clinically effective BDZs and
barbiturates generalized with the standard CDP treatment.
Other drugs such as chlorpr omaz ine
,
haloperidol,
thalidomide, and baclofen reliably produced saline lever
US
selection, even at doses that reduced responding by as much
as 80 percent (Colpaert et al
.
, 1 976 ) . Taken together,
these results demonstrate that the discriminative stimulus
produced by BDZs might be relevant to the clinical effects
of this class of drugs, and secondly that the discrim-
inative properties constitute a pharmacologically highly
specific phenomenon. It has even been suggested that the
BDZ-saline drug discrimination paradigm may represent an
animal test predictive of anxiolytic activity (Lai and
Sherman, 1982).
It has been reported that CL 218,872, a synthetic non-
BDZ compound in the triazolopyridazine class selectively
displaces 3H-diazepam from its binding sites with a potency
intermediate between that of diazepam and CDP (Squires et
al., 1979). Similar to the BDZs, CL 218,872 increases
punished responding in a conflict situation and protects
against penty lenetetrazol-induced convulsions, pharmaco-
logical properties that are highly predictive of anxiolytic
activity (Lippa et al . , 1 979). However, unlike the BDZs,
CL 218,872 was relatively devoid of depressant side effects
and was very weak in its ability to inhibit the convulsions
produced by bicuculline and strychnine (Klepner et al .
,
1979) .
The purpose of the present experiment was to compare
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further CDP and CL 218,872, structurally distinct, yet
pharmacologically similar compounds. Specifically, the aim
of this study was to train rats to discriminate between CDP
and saline in a two-lever operant task, and to investigate
whether or not CL 218,872 would produce a CDP-like
discriminative cue. Last, in an effort to further evaluate
the specificity of the discriminative complex, convulsant
(pentylenetetrazol, strychnine, and bicuculline) and non-
convulsant (amphetamine) CNS stimulants were tested for
possible antagonism of any CDP stimulus generalization to
CL 218,872.
It was previously reported that pentylenetetrazol
failed to antagonize the discriminative cue produced by a 5
mg/kg dose of CDP (Colpaert, 1977). Using a modified drug
discrimination procedure originally described by Overton
(1979), it was recently shown (J.F. McElroy, unpublished
data) that in rats initially trained to discriminate 5
mg/kg CDP from saline and retrained to discriminate a lower
dose of training drug (3 mg/kg), pentylenetetrazol
successfully blocked the CDP discriminative stimulus.
Thus, in order to increase the sensitivity of this
behavioral test paradigm, all generalization tests in the
present experiment were conducted following retraining
using this reduced dose of training drug.
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Me thods and Procedure
Animals
The subjects used in this experiment were 40 male
albino rats obtained from the Holtzman Co. (Madison, WI).
Each rat weighed between 250 and 350 g at the start of the
experiment and was singly housed in a temperature
controlled room (approximately 22oC) with a 12 hr light/12
hr dark cycle (lights on at 1900 hr). Throughout the
study, all rats had free access to tap water, while availa-
bility to standard Purina Rodent Chow pellets was
restricted to a daily 4 hr period following testing. All
training and testing were done during the dark cycle, 1 hr
prior to daily feeding, Monday through Friday of each week.
Apparatus
The behavioral apparatus consisted of standard operant
chambers (Skinner boxes) housed in light-proof, sound-
attenuated, and fan- ventilated chambers. Each operant
chamber was equipped with two levers, one on either side of
a centrally placed dipper, which delivered 0.1 ml of a
liquid reinforcement for three seconds. The reinforcement
mixture was 25% Liquid Similac, 25% condensed milk, and 50%
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tap water. Standard electromechanical programming and
cumulative counters were used to record and control
behavior
.
Drugs
CDP (Roche), strychnine, amphetamine, and pentylene-
tetrazol (Sigma) were dissolved in physiological saline,
whereas bicuculline (Sigma) and CL 218,872 (Lederle) were
suspended in a control solution of 20 percent propylene
glycol in water. All injections were given intraperito-
neally (i.p.) in a volume of 2 ml/kg body weight.
Procedure
Following habituation to the experimental chamber and
preliminary shaping, the animals were trained to alternate
between response levers on a schedule of continuous
reinforcement (only one lever was reinforced for 5 min,
then the other, for a total of 30 min). Once lever pres-
sing was well established, the reinforcement contingency
was increased incrementally to a fixed ratio 10 (FR 10)
schedule of reinforcement, while maintaining the lever
al ter nation.
Next, animals were trained to discriminate between 5
mg/kg CDP and physiological saline. Half of the rats were
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randomly assigned the left lever as "CDP-correct " and the
right lever as "saline-correct", while the lever assignment
was reversed for the remaining animals. Every tenth
response on the "CDP- correct " lever led to reinforcement on
days when animals were given CDP, whereas the opposite
lever was reinforced followed saline injections. Daily
saline or CDP treatments, each given 30 min prior to the
beginning of testing, were given according to the following
two weekly alternating sequences: CDP-saline-saline-CDP-
CDP, and saline-CDP-CDP-saline-saline. Discrimination
sessions, 10 min in duration, were continued until each
animal reached the performance criterion of no more than
three incorrect responses before the first reinforcement on
9 out of 10 consecutive sessions.
After each animal attained this initial training
criterion, the dosage of CDP was reduced to 3 mg/kg and
discrimination training was resumed until each animal again
attained the performance criterion of three or fewer
errors prior to the initial reinforcement on 9 out of 10
consecutive days.
Following retraining using 3 mg/kg CDP, a test session
was conducted on Friday of each week. On Monday through
Thursday, training sessions in the order of saline-CDP-CDP-
saline were continued for the purpose of providing
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appropriate baseline data and to ensure that discrimination
was intact. If any animal failed to demonstrate reliable
discrimination (each day with three or fewer errors),
testing using that animal was postponed and discrimination
training continued until this performance criterion was
attained. For the stimulus generalization experiments, the
training injection was replaced by an injection of CL
218,872 or by a different dose of the training drug. in
the stimulus antagonism tests, a CNS stimulant or
convulsant was administered concurrently with a dose of CL
218,872. During test sessions, 10 min in duration, the
lever on which the rat first totalled 10 responses was
reinforced and subsequent FR 10 reinforcement was made
contingent upon pressing this "selected" lever.
Data analysis
The accuracy of lever selection for each animal was
computed as the percentage of responses on the CDP-correct
lever at the occurrence of the first reinforcement. For
example, if a rat responded three times to the saline
lever before making 10 responses on the CDP lever, the cue
detection score for that animal would be 10/13 or 77
percent; if a rat made one response on the CDP lever and 10
responses on the saline lever the score would be 1/11 or
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9.1 percent. Thus, high scores indicated preference for
the CDP lever and low scores indicated preference for the
saline lever. For each generalization or antagonism test
treatment, 7-10 animals, randomly selected from the pool of
animals available for testing, were assigned to each dose
group. Thus, for each test treatment, no animal received
more than one drug dose.
Resul ts
Baseline data
All rats reliably learned to discriminate 5 mg/kg CDP
from saline, requiring a median number of 27 training
sessions (including the 10 criterion sessions) in order to
meet the performance criterion of fewer than three errors
per session on 9 out of 10 consecutive sessions. When the
training dosage of CDP was reduced to 3 mg/kg, discrim-
ination was easily maintained, with a median number of 11
additional training sessions (including the 10 criterion
sessions) required to reattain the performance criterion.
On the standard saline and CDP discrimination sessions
conducted Monday through Thursday of each week following
the retraining period, all animals reliably selected the
injection appropriate lever after either saline or CDP
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treatment. Incorrect lever selection occurred rarely and
each rat reached a highly significant level (one-tailed;
Binomial-test; p < 0.001) of correct lever selection. The
median percent-correct lever selection value was 100
percent for each animal following either CDP or saline
administration.
Stimulus generalization and antagonism experiments
The data from the stimulus generalization experiments
with CDP and CL 218,872 are summarized in Figure 1. The
training dose of CDP (3 mg/kg) generalized to lower doses
of CDP (0.5 to 2.0 mg/kg) in a dose dependent fashion. CDP
produced a dose related increase in responding, with the
response rate following 2.0 and 3.0 mg/kg significantly
above saline (control) levels. CL 218,872 (0.5 to 10.0
mg/kg) produced CDP lever selection in a dose related
manner and therefore generalized to the standard 3 mg/kg
CDP treatment. However, only three of the 10 rats tested
with the largest dose of CL 218,872 (10 mg/kg) responded
sufficiently (10 times to either lever) to indicate a lever
preference. The rest were mostly inactive during the test
session. Whereas CL 218,872 (0.5 to 5.0 mg/kg) failed to
significantly alter total responding, the highest dose
tested (10 mg/kg) suppressed responding nearly completely.
Q
HI
COP CL 218,872
Fig. 1. Stimulus generalization between
CDP and CL 218,872. Percent CDP cue
detection refers to the percentage of
responses emitted on the CDP lever at
the occurrence of the first reinforce-
ment. Nr/Nt represents the number of
rats responding sufficiently to demon-
strate lever selection, out of the total
number of rats tested. The response
level indicates the mean (+. S.E.) number
of responses for 10 min is expressed as
a percentage of the previous control
performance. The squared data point
indicates the mean number of responses
for 10 previously drug-naive rats. The
asterisks denote values that differ
significantly (Wilcoxon test; p < 0.05)
from the corresponding saline values.
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on
In marked contrast to the effect of CL 218,872
responding in CDP trained animals (90.1 % of control
levels), 5 mg/kg CL 218,872 significantly depressed
responding (46.9 percent of control) in drug naive rats.
The results of the stimulus antagonism experiments are
shown in Figure 2. Following concomitant treatment with CL
218,872 (5 mg/kg) and either bicuculline (1.0 to 4.0 mg/kg)
or strychnine (0.5 to 2.0 mg/kg), the animals continued to
select the CDP lever, thus demonstrating that the
generalization of CL 218,872 to the standard CDP treatment
had not been antagonized. However, the concurrent
administration of CL 218,872 (5.0 mg/kg) and either
pentylenetetrazol (5.0 to 20.0 mg/kg) or amphetamine (0.5
to 2.0 mg/kg) caused the rats to select the saline lever in
a dose dependent fashion, indicating that perception of the
CDP cue, otherwise evident after a 5 mg/kg injection of CL
218,872, had been antagonized. When administered alone,
each of these stimulants reliably produced saline lever
selection (Binomial test; p < 0.005). The response rate
following the acute administration of CL 218,872 (5.0
mg/kg) was not significantly altered by the concurrent
administration of any of these CNS stimulants.
Discussion
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Fig. 2. Effects of pentylenetetrazol,
bicuculline, strychnine, and amphetamine
on the generalization of CL 218,872 (5
mg/kg) to the CDP discriminative
stimulus. The ordinates and Nr/Nt are
similar to those in Fig. 1 . The dashed
areas represent the cue detection and
response values in test sessions with 5
mg/kg CL 218,872 only.
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The results of this study demonstrate that rats
previously trained to discriminate 5 mg/kg CDP from saline
can easily discriminate a dose as low as 3 mg/kg. We have
also clearly shown that CL 218,872, a synthetic non-BDZ
ligand for the BDZ receptor, produces CDP lever selection
in a dose related manner and thus generalizes to the
standard CDP treatment. It is further shown that cue
detection following injection of CL 218,872 is independent
of the rate of responding since generalization occurs at a
dose (5 mg/kg) that does not significantly alter the rate
of lever pressing. The demonstration that 10 mg/kg CL
218,872 virtually abolished responding is at odds with a
previous report that a much larger dose of CL 218,872 (223
mg/kg) is required to reduce locomotor activity by 50
percent (Lippa et. al
. 1979). However, this discrepancy
may be due to methodological differences since their drug
to test interval was 60 min and they administered CL
218,872 orally. Furthermore, motoric activity as estimated
by lever pressing for a milk reinforcement might not be
equivalent to locomotor activity as measured by an activity
meter ( Animex)
.
It is well known that BDZs produce an initial general
depression or sedation, usually shown by a decrease in
unpunished responding or exploratory behavior, an effect
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which disappears after a few BDZ treatments (Zbinden and
Randall, 1 9 6 7 ; Margules and Stein, 1968) . in the present
experiment CL 218,
8
7 2 (5 mg/kg) significantly depressed
responding in previously drug-naive rats (shown by the
squared data point in Figure 1), whereas this same dose did
not affect responding in animals that had been repeatedly
injected with CDP. These data suggest that cross tolerance
to the initial sedative effect of CL 218,872 may have
developed between CDP and CL 218,872. However, clarifica-
tion of this issue will require a more complete
investigation.
CL 218,872 potently antagonizes the convulsions
produced by pentylenetetrazol, but unlike the BDZs is very
weak in its ability to inhibit the convulsions produced by
bicuculline or strychnine (Lippa et al
. ,
1979). Consistent
with this specificity, the data reveal that the generaliza-
tion of the CDP discriminative stimulus to CL 218,872 is
antagonized by pentylenetetrazol and amphetamine, but not
by bicuculline or strychnine. This suggests that stimulus
generalization is not associated with a general anticon-
vulsant activity but rather is associated with a specific
antipenty lenetetrazol effect. This mutual antagonism
between pentylenetetrazol and CL 218,872 may indicate that
the same neuronal mechanism subserves both the antipen-
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tylenetetrazol and discriminative stimulus properties of
the BDZs.
It has been proposed that two biochemically and
pharmacologically distinct types exist among central type
BDZ receptors (Klepner et al
. , 1979). Type I receptors are
GABA-independent, display a high affinity for both BDZs and
TPZs, and are presumed to mediate the anxiolytic and
antipentylenetetrazol actions of these drugs. Type II
receptors are GAB A-dependent
, show a high affinity for BDZs
but a low affinity for TPZs, and are believed to mediate
the depressant side effects associated with the BDZs. In
the interest of establishing whether BDZ discriminative
cues can be traced to one receptor type or the other, the
present data reveal that CL 218,872 (5 mg/kg) produced a
discriminative cue without sedation, at doses similar to
those that produce anticonflict and antipentylenetetrazol
effects (Lippa et al
. ,
1979b). The present demonstration
of stimulus generalization in the absence of sedation
suggests that the discriminative stimulus properties of
BDZs may be mediated via stimulation of Type I BDZ
receptors. The demonstration that stimulus generalization
is antagonized by pentylenetetrazol but not by the GABA
receptor blocker bicuculline further supports such a
notion. It may be that the anxiolytic, antipenty lenetetra-
60
zol, and discriminative stimulus properties of BDZs are
mediated via activation of Type I BDZ receptors, whereas
the sedative and ataxic effects of BDZs are mediated
through activation of Type II BDZ receptors.
Since several neurotransmitter systems have been
postulated to be associated with the pharmacological
actions of the BDZs (for reviews, see Feldman and Quenzer,
1984;Costa and Greengard, 1975), it is difficult to
establish exactly which neurotransmitter is responsible for
the discriminative stimulus properties of this class of
drugs. However, the catecholamine agonist amphetamine, but
neither strychnine nor bicuculline ( receptor blockers for
glycine and GABA respectively, Curtis et al
. , 1970; Young
and Snyder, 1973) antagonized the stimulus generalization
of CDP to CL 218,872. This might suggest that either
norepinephrine or dopamine is involved in eliciting the BDZ
discriminative stimulus. The ability of pentylenetetrazol
to antagonize stimulus generalization does little to
clarify this issue as acetylcholine (Rastogi et al
. , 1979),
norepinephrine (Mason and Corcoran, 1978) and GABA
(Johnston and Mitchell, 1971) have been implicated in the
convulsant action of pentylenetetrazol. Clarification of
this issue will require additional research.
CHAPTER III
EXPERIMENT II
A COMPARISON BETWEEN CHLORDIAZEPOXIDE AND CL 218,872
ON LOCOMOTOR ACTIVITY IN RATS
Introduction
It has been firmly established that acute treatment
with benzodiazepines (BDZs) at clinically effective doses
produces a general depression or sedation, usually shown by
a decrease in unpunished responding, exploratory behavior,
or locomotor activity (Geller and Seifter, 1960; Zbinden
and Randall, 1967; Margules and Stein, 1968; Quenzer et
al., 1974). A number of non-BDZ compounds that bind
potently to the BDZ receptor and display a pharmacological
profile similar to that of the BDZs have recently been
introduced (for reviews, see Goldberg et al., 1983; Chapter
I). One such compound, the triazolopy ridazine derivative
CL 218,872, reportedly produces anticonflict and
anticonvulsant effects in rats at relatively low doses
(0.75 to 6.0 mg/kg p.o.), whereas ataxic and sedative
effects only become apparent at much larger doses (ED for
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sedation = 223 mg/kg p.o.).
It was demonstrated in the previous chapter (Chapter
61
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II), however, that CL 218,872 (5 mg/kg i.p.) decreased by
50 percent the rate of lever pressing for a milk
reinforcement in an operant task, an effect that appeared
to be prevented by chronic pretreatment with chlordiaz-
epoxide (CDP). The obvious discrepancy between the results
reported in Chapter II and those reported by Lippa et al.
(1979) may easily be a consequence of methodological
differences between the two experiments, however, because
motoric activity as estimated by lever pressing might not
be equivalent to locomotor activity as measured in an
activity chamber (Animex). Thus the present experiment
aimed to resolve this discrepancy by evaluating the effects
of CL 218,872 on locomotor activity as measured in an
activity chamber. For comparative purposes, the effects of
CDP were similarly evaluated. Moreover, in order to verify
the finding in Chapter II that CDP conferred a cross-
tolerance to the sedative effect of CL 218,872, additional
rats were treated with either CDP or CL 218,872 prior to
behavioral testing with these drugs.
Me thods and Procedure
Animal
s
The subjects were 60 male albino rats obtained from
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the Holtzman Co. (Madison, WI). The rats weighed 250-300 g
throughout the experiment and were housed in a temperature
o
controlled room (approximately 22 C) with a 12 hr light/12
hr dark cycle (lights on at 1900 hr). Throughout the
study, all rats had free access to tap water and standard
Purina Rodent Chow pellets. All testing was done in a
quiet darkened room between 0800 and 1100 hr.
Apparatus
The testing apparatus was a cylinder 62 cm in diameter
and 42 cm deep with a mesh floor (Lehigh Valley Activity
Box, model No. 145-03). Counters provided a record of
locomotor activity as each animal interrupted 12 light
beams that were detected by photocells equally spaced 2.5
cm above the floor along the perimeter of the testing
apparatus
.
Procedure
Animals were randomly assigned to one of 12 groups
(N =5). Following habituation to the testing apparatus
(10 min per day for six consecutive days), six groups of
rats were injected with drug vehicle on day seven, and then
with either CDP or CL 218,872 (2.5, 5, or 10 mg/kg) on day
eight. The remaining six groups were similarly treated
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except that each rat was injected on days one through six
with CDP or CL 218,872 (10 mg/kg), or with drug vehicle.
CL 218,872 (Lederle) was suspended in a solution of 20
percent propylene glycol in water, and CDP hydrochloride
(Roche) was dissolved in physiological saline. All
injections were administered i.p. in a volume of 2 ml/ kg
of body weight. On drug pretreatment days (one through
six), injections were given 30 min after the habituation
session, whereas on drug test days (seven and eight)
injections were given 30 min prior to the 10 min test
session.
Data analysis
The locomotor activity for each rat was determined by
the number of light beam interruptions following drug
treatment on day eight, and was expressed as a percentage
of the locomotor activity on day seven (control
performance). All data were subjected to t-tests and to
analysis of variance (AN0VA) as appropriate. Results
occurring with a chance probability of less than .05 were
considered statistically significant.
Resul ts
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The effects of acute CDP and CL 218,872 administration
on locomotor activity are shown in Fig. 3. The mean (± 1
S.E.) number of activity counts during the 10 min control
session (day seven) was 619 ± 37. There was no difference
in responding between saline and propylene glycol treated
rats (two-tailed; Mann Whitney test; p > 0.20). Compared
to vehicle performance, each dose of CL 218,872 (2.5, 5,
and 10 mg/kg) significantly reduced locomotor activity
(two-tailed; Wilcoxon test; p < 0.05;). The dose response
pattern following CDP administration was less consistent,
with the smallest dose (2.5 mg/kg) increasing, and the
largest dose (10 mg/kg) decreasing locomotor activity (p <
0. 05). The intermediate dose of CDP (5 mg/kg) produced a
non-significant response suppression (p > 0.10). An
overall ANOVA revealed no Drug main effect (F = 2.22; df =
1, 24; p = 0.18), a highly significant Dose main effect (F
= 20.98; df = 2, 24; p < 0.001), and a significant Drug X
Dose interaction (F = 4.35; df = 2, 24, p < 0.05).
From an examination of the dose-response relationship
for each compound, the 10 mg/kg dose was adopted as the
challenge dose in the tolerance and cross- tolerance
experiment (Fig. 4). The mean (+ 1 S.E.) number of
activity counts during the 10 min control session (day
seven) was 690 + 30. Repeated measures ANOVA of day one
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Fig. 3. Spontaneous locomotor activity in rats
measured 30 min after acute administration of CDP
or CL 218,872 at doses of 2.5, 5, and 10 mg/kg
i.p. Data represent the mean (+. 1 S.E.) for six
rats per group, and is expressed as a percentage
of the previous (day seven) vehicle performance.
The asterisks denote values that differ signifi-
cantly (two-tailed, p < 0.05, Wilcoxon test) from
the day seven vehicle performance.
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Fig. 4. The effect of CDP, CL 218,872, or
vehicle pretreatment on the suppression of
spontaneous locomotor activity produced by a test
dose of CDP or CL 218,872. The test treatment
(10 mg/kg i.p.) was given 30 min before testing
and 48 hr after six daily pretreatments (10 mg/kg
i.p.). Data represent the mean (+ 1 S.E.) for
six rats per group, and are expressed as a
percentage of the previous (day seven) vehicle
performance. The asterisks denote values that
differ significantly (two-tailed, p < 0.05,
Wilcoxon test) from the corresponding vehicle
pretretment group.
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through day seven activity counts revealed no Pretretment
(F
= 0.25; df = 2, 27; p = 0.59), and Day (F = 1. 33; d f =
6
'
162
'
p
=
°' 24
>
main effects, and no Pr etreatment X Day
interaction (F = 0. 7 2; df = 12, 162, p = 0.73). Thus, the
six daily post-training drug injections had no cumulative
effect on baseline locomotor activity. Analysis of
variance of day eight scores expressed as a percentage of
the day seven control performance revealed no Test
Treatment main effect (F = 2.66, df = 1, 24, p = 0.16), but
a reliable Pretreatment main effect (F = 6.19, df = 2, 24,
P < 0.01), and a highly significant Pretreatment X Test
Treatment interaction (F = 7.48, df = 2, 24, p < 0.005).
Post-hoc testing indicated that the suppression of
locomotor activity produced by CDP (10 mg/kg) was clearly
attenuated by six daily pre treatments of either CDP or CL
218,872 at the same dosage (Fisher's Least Significant
Difference Test; p < 0.05). In marked contrast to the
situation using CDP, however, the response suppression
produced by CL 218,872 (10 mg/kg) was not significantly
altered by CDP or CL 218,872 pretreatment (p > 0.05).
Pi scussion
Consistent with previous reports (Sansone, 1979;
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Herberg and Williams, 1983)
,
acute administration of CDP
produced a dose-dependent effect on locomotor activity. A
low dose of CDP (2.5 mg/kg) increased activity, whereas a
relatively high dose (10 mg/kg) decreased activity. A
single challenge injection of CL 218,872 (2.5, 5, and 10
mg/kg) significantly reduced locomotor activity, a finding
in agreement with the earlier demonstration in Chapter II
that CL 218,872 (5 mg/kg) reliably suppressed lever
responding in an operant task. The route of drug
administration and the drug to test interval were the same
in both experiments. On the other hand, the present report
is at variance with the report by Lippa et al . ( 1 979) that
a 223 mg/kg dose of CL 218,872 was reqiured to reduce
locomotor activity by 50 percent. It is possible, however,
that this 20-fold disparity in drug potency may still be
due to methodological differences since their drug to test
interval was 60 min and they administered CL 218,872 by the
oral route.
Pretreatment with CDP or CL 218,872 (10 mg/kg once
daily for six days) produced tolerance and cross- tolerance
respectively to the sedative effects of a single injection
of CDP. Hoogland et al . (1966) demonstrated that chronic
CDP treatment (100 mg/kg for five days) decreased the
14
blood concentration of subsequently administered C-CDP,
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suggesting that the tolerance reported here and in many
previous experiments (Margules and Stein, 1968; Cook and
Sepinwall, 1 975 ; Sansone, 1 979) may be a result of
increased hepatic metabolism of the drug. Although chronic
pretreatment with ethanol similarly decresed the blood
concentration of CDP (Sellers and Busto, 1982), it cannot
be established from the present data whether the CL
21 8,872-induced cross- tolerance to the sedative action of
CDP is enzymatic, cellular, or behavioral in nature.
In marked contrast to the situation using a challenge
dose of CDP, chronic CDP or CL 218,872 pretreatment did not
attenuate the activity-suppressant action of acute CL
218,872 administration. The previous experiment (Chapter
II) suggested that CDP pretreatment (three to four
injections per week for 10 weeks) conferred a cross-
tolerance for the sedative effects of CL 218,872, a finding
not supported by the present data. Whether the development
of tolerance and cross- tolerance to the sedative effects of
CL 218,872 is dependent upon the number and/or duration of
pre treatments remains to be established.
However, the demonstration of asymmetry in the
development of tolerance and cross- tolerance is not without
precedent. For example, morphine pretreated mice showed
little or no cross- tolerance to either etorphine or
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ne
ne-
methadone analgesia, whereas either etorphine or methadone
pretreated mice were highly cross- tolerant to morphi
(Lange et al
.
,
1980; Neil, 1982). Similarly, fenflurami
tolerant rats were cross- tolerant to the anorectic effects
of quipazine, but quipazine-tolerant animals were not
cross-tolerant to fenfluramine (Rowland et al., 1982).
Although the precise mechanisms responsible for such
differences in the development of tolerance and cross-
tolerance cannot be determined from the present data, Neil
(1982) has suggested that this complex phenomenon of
asymmetry in cross- tolerance may be due to receptor
heterogeneity at the single cell level. That is, neurons
desensitized to compound A become subsensitive to compound
B, whereas cells desensitized to B remain sensitized to A.
Just such an asymmetry in acute desensitization in rat
cortical neurons was reported for methionine-enkephalin and
morphine (Williams and Zieglgansberger
,
1981). An
alternative possibility is that the asymmetry is due to
differential metabolic processes about which, unfortun-
ately, one can only speculate.
CHAPTER IV
EXPERIMENT III
EFFECTS OF CHLORDI AZEPOXIDE AND CL 218,872 ON
SEROTONIN AND NOREPINEPHRINE TURNOVER IN RATS
Introduction
Acute treatment with benzodiazepines (BDZs) at
clinically effective doses produces a general depression or
sedation, usually shown by a decrease in unpunished
responding (Geller and Seifter, 1960; Margules and Stein,
1968), exploratory behavior (Zbinden and Randall, 1967), or
locomotor activity (Quenzer et al
. , 1974; Chapter III). It
is this general depressant effect upon the CNS that forms
the basis for their clinical use as sedative-hypnotics (for
review, see Greenblatt et al
. ,
1982). In fact, most BDZs
can be prescribed as antianxiety agents at low doses, and
as sedative-hypnotics at higher doses. It is still
controversial, however, whether, or to what extent, the
anxiolytic and sedative effects produced by these drugs can
be dissociated. Support for such a possibility has been
recently advanced by the development of a number of novel
anxiolytic drugs purported to be devoid of the depressant
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side effects typically associated with BDZ use (for review,
see Goldberg et al., 1983).
Geller and Seifter (I960) devised a technique by which
behavioral pharmacologists can comparatively study the
anxiolytic and sedative effects of a drug. Briefly, a
conflict situation (punished schedule) is systematically
alternated with positively reinforced behavior (nonpunished
schedule). An increase in frequency of the punished
behavior brought about by a drug is interpreted as an
antianxiety effect, while a decrease in frequency of the
nonpunished behavior is regarded as a sedative effect.
This technique offers the important advantage of studying
both behavioral effects in the same animal and within the
same experimental paradigm, thus reducing the influence of
extraneous variables.
Using a modified version of the Geller and Seifter
technique, Margules and Stein (1968) found that the depres-
sant and anticonflict effects of BDZs may be dissociated
after chronic administration of these agents. When a rat
not previously exposed to drugs was given the BDZ oxazepam
(20 mg/kg i.p.), unpunished responding was suppressed on
the first day of drug administration (sedative effect),
whereas punished responding was slightly greater than in
control tests (anxiolytic effect). After three to six
74
daily doses, unpunished responding returned to control
levels, indicating that tolerance had developed to the
depressant effect of oxazepam whereas increases in punished
responding persisted, indicating that tolerance had not
developed to the anticonflict effect of the drug.
Many pharmacological agents have been evaluated using
this rat conflict-punishment procedure. The ability to
restore punishment-suppressed responding has been extended
to additional BDZs such as chlordiazepoxide (CDP),
bromazepam, f luni tr azepam
,
lorazepam, clonazepam and
diazepam, as well as to other non-BDZ anxiolytics such as
meprobamate, phenobarbi tal
,
amobarbital, and ethanol. A
broad variety of non-anxioly tic psychotropic drugs such as
chlorpromazine, haloperidol, imipramine, morphine, amphet-
amine, and iproniazid were all ineffective in this
procedure (Cook and Davidson, 1973; Cook and Sepinwall,
1975), indicating that the rat conflict-punishment test is
qualitatively selective for clinically effective anxiolytic
agents. This test has also provided a good quantitative
estimate of the relative clinical potency of a test
compound. Specifically, Cook and Davidson (1973) reported
a correlation coefficient of + 0.98 between the minimum
effective anticonflict dose in rats for six minor
tranquilizers and their average daily dose used for
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treating psychoneurotic disorders. Anticonflict activity
in rats has been more recently demonstrated for a number
of novel anxiolytics such as CL 218,872 (Lippa et al.,
1979)
,
zopiclone (Sepinwall and Cook, 1980), and buspirone
(Weissmann et al
. , 1 984), further illustrating the utility
of the rat conflict-punishment procedure in predicting a
drug's potential efficacy as a clinical anxiolytic agent.
Despite considerable evidence to suggest that many, if
not all, of the effects of BDZs in the central nervous
system may be explained by their ability to enhance GABA
mediated transmission (for review, see Tallman et al.,
1980)
,
there is also convincing evidence supporting a role
for brain 5-hy dr oxy try p tamine (5-HT, serotonin) in at least
the anticonflict effects produced by BDZs. This evidence
includes studies showing that an inhibitor of 5-HT biosyn-
thesis, p-chlorophenylalanine (PCPA), as well as the 5-HT
receptor antagonists cinanserin and methysergide , can
produce BDZ-like effects in the rat conflict test (Stein et
al., 1973; Cook and Sepinwall, 1975). Moreover, the
immediate 5-HT precursor, 5-hy droxy tryptophan (5-HTP),
reversed the anticonflict effects produced by PCPA and
cinanserin (Geller and Blum, 1970; Geller et al., 1974).
Anticonflict effects have also been observed after destruc-
tion of central 5-HT neurons by direct administration of
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the neurotoxins 5,6- and 5 . 7-dihy droxy tryptamine into the
brain (Stein et al
. , 1977; Tye et al., 1977). Furthermore,
intracerebroventricular (i.e. v.) injection of 5-HT counter-
acted the anxiolytic effects of BDZ administration (Wise et
al., 1972). Taken together, these and other experiments
indicate that 5-HT may play a role in the antianxiety
properties of BDZs.
Since the original discovery by Olds and Milner (1954)
of the rewarding properties of brain stimulation, research
findings compiled over the past 20 years have characterized
a brain reward system as catecholaminergic and a brain
punishment system as mainly serotonergic (for review, see
Deakin (1983). Thus, early BDZ research focused primarily
on brain norepinephrine (NE) and 5-HT systems. In an effort
to determine whether the antianxiety and sedative effects
of BDZs could be correlated with changes in turnover rates
of 5-HT and/or NE (Corrodi et al., 1967; Taylor and
Laverty, 1969; Chase et al
. ,
1970), Wise et al. (1972)
administered a single dose or six daily doses of oxazepam
to rats and measured the turnover rates of NE and 5-HT in
the midbrain-hindbr ain region. A single injection of
oxazepam (20 mg/kg i.p.) significantly reduced both 5-HT
and NE turnover rates. Rats sacrificed after the sixth
daily dose of oxazepam showed a significant decrease in
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the turnover rate of 5-HT, but not of NE . In other words,
following chronic administration of this BDZ, tolerance
developed to the reduced turnover rate of NE, but not to
that of 5-HT. As noted previously, under these same
conditions tolerance developed to the behavioral depression
induced by oxazepam, but not to the anticonflict effect.
From these results Wise et al. (1972) concluded that the
depressant effect of BDZs may be associated with reduced NE
turnover, and the anticonflict effect with reduced 5-HT
turnover
.
Using a different BDZ, however, Cook and Sepinwall
( 1 975) were unable to fully replicate the Wise et al
.
(1972) findings. While producing behavioral effects and 5-
HT turnover effects consistent with those produced by
oxazepam, CDP (10 mg/kg p.o.) had the exact opposite
effects on NE turnover. Specifically, NE turnover was
unchanged following acute CDP treatment (at which time
unpunished responding was significantly depressed), but was
significantly reduced following repeated CDP administration
(at which time a marked depression of unpunished responding
was no longer evident). Thus, the Cook and Sepinwall
(1975) data are inconsistent with the Wise et al. (1972)
proposal that the initial sedative effects produced by BDZs
are related to decreased NE turnover. It should be pointed
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out, however, that the discrepancies obtained between these
two studies may be accounted for by methodological
differences such as the route of drug administration and
the brain region analyzed (Cook and Sepinwall assayed whole
brain )
.
Since the BDZs alter both 5-HT and NE neuronal systems
in the same dose range that they produce antianxiety and
sedation, it has not been possible to establish conclu-
sively that the anxiolytic and sedative effects of these
compounds are mediated by reductions in 5-HT and NE
turnover respectively. However, the development of TPZs
affords a unique opportunity to further assess the
importance of brain 5-HT and NE systems in contributing to
the anxiolytic and sedative actions produced by BDZs.
Furthermore, because CL 218,872 is a BDZ receptor agonist
with a selective affinity for Type I BDZ receptors (Squires
et al., 1979), examination of CL 218,872 might further
establish the role, if any, of this BDZ receptor subtype in
mediating the BDZ effects on 5-HT and NE neurotransmission.
To this end, 5-HT and NE turnover in the midbrain-hindbrain
region of the rat brain were assessed after acute and
chronic administration of CL 218,872, the prototypical
tr iaz ol opy ridaz ine . For comparative purposes, and in an
effort to further resolve the disparity between Wise et al
.
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(1972) and Cook and Sepinwall (1975), the effects of CDP on
5-HT and NE turnover were similarly evaluated using the
brain region and route of drug administration employed by
Wise et al . (1 972 ) .
The rate of synthesis of catecholamines (CA) and 5-HT
in brain was determined following treatment with NSD 1015
(3-hydroxybenzyl hydrazine HC1). NSD 1015 is a powerful
inhibitor of aromatic L-amino acid decarboxylase, the
enzyme responsible for converting 5-HTP to 5-HT, and
dihydroxyphenylalanine (DOPA) to dopamine, which of course
can then be converted to NE. Because the rate limiting
steps in 5-HT and CA synthesis occur prior to the enzymatic
block, the accumulated levels of 5-HTP and DOPA should
reflect the rates of 5-HT and CA synthesis (turnover) in
experimental vs. control subjects (Pycock and Taberner,
1981). The results of the NSD method agree quite well wd th
those of other methods for estimating the rate of brain
biogenic amine synthesis (Carlsson et al., 1972; Curzon,
1981 ). The NSD method offers the obvious advantage of
measuring both 5-HT and CA turnover in the same animal.
Furthermore, because brain levels of 5-HTP and DOPA are
virtually negligible, and because the accumulation of each
of these compounds is linear for up to 30-45 min following
decarboxylase inhibition (Carlsson et al
. ,
1972; Carlsson
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and Lidquist, 1970), synthesis rates can be determined from
a single measurement. The major weakness of the NSD
method, however, is that it is unable to differentiate
between the rates of DA and NE synthesis in regions where
both neurotransmitters are found. As estimated from a rat
brain stereotaxic atlas, the midbrain-hindbrain section
used in the present experiment probably contains all 5-HT
cells from the B1 to B9 nuclei, all NE cells from the A1 to
A7 nuclei, and some DA cells from the A8 and A10 nuclei
(the rostral dissection traversed directly through the DA
containing A8 and A10 nuclei in the ventral and ventro-
lateral midbrain tegmentum, while excluding the A9
nucleus). Inclusion of these DA cells was unavoidable in
order that our tissue section contain the 5-HT cells
located in the B7 and B8 nuclei, which are the source of
approximately 80 percent of all forebrain 5-HT terminals
(Azmitia, 1978). Furthermore, in order to make valid
comparisons to the study by Wise et al . (1972), it was
important to use their dissection coordinates. Thus, the
relative contribution of DA in the overall measure of CA
turnover in the present study cannot be precisely
determined, and the values obtained will probably over
estimate the actual rate of NE synthesis.
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Methods and Procedure
Animals
Adult male albino rats were bred in our laboratory
from stock animals obtained from the Holtzman Co. (Madison,
WI) and were housed in a temperature controlled room
o
(approximately 22 C) under a 14:10 light-dark cycle
(lights on at 0600 hr). Rats were housed in group cages
until they weighed 200-225 g, at which time they were
removed to single cages. Tap water and standard Purina
Rodent Chow pellets were available ad libitum.
Drugs
CL 218,872 (Lederle) was suspended in a solution of
20% propylene glycol in water, whereas CDP (Roche) and NSD
1015 (Sigma) were dissolved in physiological saline. All
injections were given intraperitoneally (i.p.) in a volume
of 2 ml/kg body weight.
Procedure
Half of the animals were given a single injection of
CDP, CL 218,872, or drug vehicle. The remaining animals
were given seven daily drug or vehicle injections (days one
through six and day eight). The drug dosages are indicated
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in each table. Thirty min following the last drug or
vehicle injection each animal received NSD 1015 (100
mg/kg), and thirty min after that the rats were
decapitated, their brains immediately removed and the
midbrain-hindbrain region rapidly dissected on an ice-cold
glass plate. A vertical knife cut was made through a plane
beginning on the dorsal surface of the brain just rostral
to the superior colliculus and ending on the ventral
surface just caudal to the mammillary bodies. The
posterior transection was made perpendicular to the obex,
with the cerebellum discarded. Immediately after
dissection, the tissue was weighed, homogenized in ice-cold
0.4 N perchloric acid containing 0.025$ ascorbic acid and
0.25? EDTA, and then centrifuged at 30.000 x g for 10 min
at OoC. Supernatants were treated with KOH to adjust the
pH to 2.5, and centrifuged at 30,000 x g for 5 min at OoC
to remove the perchlorate by precipitation of the insoluble
potassium salt. The resulting extracts were applied to
small columns of Dowex 50W-X4, 200-400 mesh, a strong
cation-exchange resin (Atack and Magnusson, 1970). Both
the 5-HTP and DOPA were eluted in 1.5 ml 0.01 M sodium
phosphate buffer. The well established o-phthaldialdehyde
(Maickel and Miller, 1966) and potassium ferricyanide (Kehr
et al . , 1 972) fluorometric methods were used to measure 5-
83
HTP and DOPA respectively. Fluorescence was measured using
a Perkin-Elmer #1000 spectrof luorometer using activation
and emission wavelengths of 364/480 and 364/500 for 5-HTP
and DOPA respectively. Standards were run in parallel with
the samples in each assay.
Data analysis
All data (presented as the mean + 1 S.E.) were
subjected to analysis of variance (ANOVA) followed by
individual mean comparisons using Fisher's Least
Significant Difference Test (Kirk, 1968) where appropriate.
Results occuring with a chance probability of less than .05
were considered statistically significant.
Resul ts
Each tissue sample consisted of one midbrain-hindbrain
region (356 + 11 mg wet weight) from a single rat.
Recoveries of 22.5 ng of 5-HTP and DOPA added to
homogenates of single midbrain-hindbrain samples were 69.3
+ 5.2 and 66.9 ± 4.7 percent respectively.
The effects of CDP and CL 218,872 on 5-HTP
accumulation in rats treated with NSD 1015 can be seen in
Table 1 . During the first 30 min after administration of
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Table 1. Effects of chlordiazepoxide and CL 218,872
administration on 5-HTP accumulation in the midbrain-
hindbrain of rats treated with NSD 1015.
In.1 ection Schedule
Acute Chronic
Drug Dose
(mg/kg) ng/g 11 control
)
11 control
^
Chlordiaz-
epoxide
0 552 +_ 23 528 +_ 34
2.5 529 29 (94) 433 _+ 22 (82) »
5 440 ± 16 (80) * 448 +_ 21 (85) *
10 406 21 (74) « 348 +. 30 (66)
20 395 _+ 27 (72) * 385 +. 19 (73) *
CL 218,872
0 513 +_ 39 522 +, 31
2.5 490 +_ 17 (96) 493 + 24 (94)
5 549
_+ 33 (107) 506 ± 23 (97)
10 563 + 26 (110) 489 18 (94)
20 451 21 (88) 538 ± 26 (103)
NSD 1015 (100 mg/kg) was given 30 min after the final drug
or vehicle treatment and 30 min before the rats were
killed. Chronically treated animals received their final
drug or vehicle treatment 48 hr after 6 consecutive daily
pr etreatments at the same dosage. Data represent the mean
+ S.E. for 5 rats per group. *signif icantly different (at
least p < 0.05) from the corresponding vehicle (0 mg/kg)
treated group.
85
NSD 1015, the mean concentration of 5-HTP in midbrain-
hindbrain increased from essentially zero (0.07 ng/g) to
529 ± 17 ng/g. This accumulation of 5-HTP (uncorrected for
percent recovery) corresponds to a 5-HT synthesis
(turnover) rate of 1058 ng (4 .8nmoles)/g tissue/hr. ANOVA
revealed highly significant Drug (F = 19.99, df = 1, 92, p
< 0.0001) and Dose (F = 13.83, df = 4, 9 2, p < 0.0001) main
effects, but no Pretreatment main effect (F = 0.75, df = 1
,
92, p = 0.39). The only significant interaction was that
of Drug X Dose (F = 6.65, df = 4, 92, p < 0.001). Post-hoc
testing showed that the formation of 5-HTP was not affected
by either the number of vehicle injections (one or seven)
or the type of vehicle administered (saline or propylene
glycol solutions). A single injection of CDP (2.5 to 20
mg/kg) decreased the concentration of 5-HTP, with the 5,
10, and 20 mg/kg doses significantly different from tJae
control (0 mg/kg) group. Despite the appearance of a dose-
dependent trend toward diminished 5-HTP concentrations, no
statistically significant differences occured between the
5, 10, and 20, mg/kg doses. The decreased accumulation of
5-HTP persisted after chronic CDP administration, with all
doses (2.5 to 20 mg/kg) producing reliable differences from
the control (0 mg/kg) group. Only the lowest dose tested
(2.5 mg/kg), however, was more effective at reducing 5-HTP
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formation after seven drug injections than after a single
drug injection. In marked contrast to the situation using
CDP, neither acute nor chronic administration of CL 218,872
reliably altered the accumulation of 5-HTP after
decarboxylase inhibition.
Table 2 shows the effects of CDP and CL 218,872 on
DOPA accumulation after treatment with NSD 1015. The
concentration of DOPA in midbrain-hindbrain increased from
an unmeasurable level (with a detection limit of 0.03 ng/g)
to an average value of 149 ± 8 ng/g/30 min. This
accumulation of DOPA represents a CA synthesis (turnover)
rate of 298 ng (1.48 nmoles/g tissue/hr. ANOVA revealed
significant Dose (F = 3.82, df = 4, 92. p < 0.01) and
Pretreatment (F = 7-04, df = 1, 92, p < 0.01) main effects,
in addition to marginally significant Drug X Dose (F =
2.51, df = 4, 92, p < 0.05) and Drug X Dose X Pretreatment
(F = 2.69, df = 4, 92, p < 0.05) interactions. As was the
situation with 5-HTP formation, DOPA formation was not
affected either by the number of vehicle injections or by
the type of vehicle administered. Although a single
injection of CDP (2.5 to 20 mg/kg) failed to influence DOPA
accumulation in midbrain-hindbrain, chronic CDP administra-
tion at the same doses did reduce DOPA concentrations, with
all but the largest dose tested (20 mg/kg) significantly
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Table 2. Effects of ehlordiazepoxide and CL 218,872
administration on DOPA accumulation in the midbrain-
hindbrain of rats treated with NSD 1015.
Drug Dose
(mg/kg)
In.i ection Schedul e
Acute Chronic
n fi/K XI control) ng/g XI contro:
uniorQisz-
epoxide
0 144
_+ 1 2 141 +, 1 0
2.5 135 ±_ 9 (94) 108
_+ 8 (82) *
5 122
_+ 1 2 (85) 94 + 9 (68) *
1 0 148
_+ 9 (103) 107 ± 6 (77)
20 1 32 + 20 (92) 120 ±_ 14 (86)
CL 218,872
0 149 +_ 1 2 155 +, 13
2.5 132 +_ 1 0 (88) 149 +, 1 1 (96)
5 146 +_ 16 (98) 129 +, 1 1 (83)
1 0 128 +_ 8 (86) 172 + 17 (111)
20 164
_+ 21 (110) 163 14 (105)
NSD 1015 (100 mg/kg) was given 30 min after the final drug
or vehicle treatment and 30 min before the rats were
killed. Chronically treated animals received their final
drug or vehicle treatment 48 hr after 6 consecutive daily
pr etreatments at the same dosage. Data represent the mean
+. S.E. for 5 rats per group. *signif icantly different (at
least p < 0.05) from the corresponding vehicle (0 mg/kg)
treated group.
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different from the control (0 mg/kg) group. Similar to its
effect on 5-HTP formation, CL 218,872 (2.5 to 20 mg/kg),
whether administered only once or seven times, had no
reliable affect on DOPA formation.
Discussion
The present results demonstrate that 5-HT turnover, as
measured by the accumulation of 5-HTP after decarboxylase
inhibition by NSD 1015, was significantly reduced following
both acute (5 to 20 mg/kg) and chronic (2.5 to 20 mg/kg)
CDP administration. These results are in agreement with
previous reports showing that CDP reduced 5-HT turnover in
whole brain (Cook and Sepinwall, 1975), cerebral cortex
(File and Vellucci, 1978), and hippocampus (Lister and
File, 1983). Moreover, this effect does not appear to be
unique to CDP since 5-HT turnover is similarly reduced by
other BDZs such as diazepam (Biswas and Carlsson, 1978;
Jenner et al., 1975; Chase et al., 1970), clonazepam
(Jenner et al., 1975), and oxazepam (Wise et al
. ,
1972), as
well as by other non-BDZ anxiolytics such as pentobarbital
(Corrodi et al . , 1 967), and dipheny lhydantoin (Jenner et
al
. ,
1975). Thus, the 5-HT turnover results reported here
are fully consistent with, and further support the
89
hypothesis first proposed by Wise et al . (1 97 2) that BDZs
may be exerting their antianxiety effects by a reduction in
5-HT neurotransmission.
Reports concerning the effects of BDZs on NE turnover,
however, have been less consistent. For example, a single
injection of oxazepam decreased NE turnover (Wise et al.
1972), whereas NE turnover after a single treatment with
CDP was no different from that in control animals (Corrodi
et al., 1967; Corrodi et al., 1971; Cook and Sepinwall,
1975). Following repeated administration, however, just
the opposite occurred, with oxazepam leaving unchanged
(Wise et al., 1972), and CDP decreasing (Cook and
Sepinwall, 1975) NE turnover. In the present experiment,
acute injection of CDP (2.5 to 20 mg/kg) left CA turnover
unchanged from control values, whereas seven daily
injections of CDP (2.5 to 10 mg/kg) significantly lowered
the CA turnover rate. Thus, the present findings confirm
the Cook and Sepinwall (1975) report in whole brain using
CDP, and extend their findings to midbrain-hindbrain.
Furthermore, this study demonstrates that the discrepancies
between Wise et al. (1972) and Cook and Sepinwall (1975)
are not due either to the route of drug administration
(i.p. vs. p.o.) or to the brain region assayed (midbrain-
hindbrain vs. whole brain). Therefore, despite having
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similar effects on unpunished responding after acute
administration, CDP and oxazepam appear to have very
different effects on NE turnover. Taken together with
previous reports, our data do not lend support to the
proposal by Wise et al
. (1972) that, in general, BDZs exert
their acute depressant effects by a reduction in NE
neurotransmission. Rather it appears that the effects of
BDZs on brain NE activity might be specific for the BDZ
under consideration. It should be emphasized, however,
that our data do not exclude the possibility that at least
oxazepam can be producing its depressant effect through a
reduction in NE turnover.
As a non-BDZ anxiolytic purported to be devoid of the
depressant side effects typically associated with acute BDZ
administration (Lippa et al
.
, 1 979), CL 2 18 ,872 offers an
opportunity to further assess the relative importance of
brain 5-HT and NE systems in contributing to the anxiolytic
and sedative actions produced by BDZs. Consistent with the
Wise et al
. (1972) proposal, CL 218,872 would be expected
to decrease 5-HT turnover, while having no effect on CA
turnover. In light of the recent demonstration that CL
218,872 produces a marked reduction in both lever pressing
(chapter 2) and locomotor activity (last chapter) under
experimental conditions identical to those employed in the
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present study, one might alternatively predict that CL
218,872 would reduce CA turnover. m the present
experiment CL 218,872 (2.5 to 20 mg/kg), whether
administered acutely or chronically, did not alter either
5-HT or CA turnover. These negative results cannot be
attributed to the experimental procedure, however, since
the results using CDP showed that this procedure can
detect changes in both 5-HT and CA metabolism in midbrain-
hindbrain. Whether or not the results obtained here are
unique to CL 218,872 or can be extended to
pharmacologically similar anxiolytic compounds such as
zopiclone (Wickstrom and Giercksky, 1980), PK 9084 (LeFur
et al., 1981), and buspirone (Weissman et al
. ,
1984)
remains to be determined.
Finally, since CL 218,872 is a BDZ agonist with a
selective affinity for Type I BDZ receptors (Squires et
al., 1979), the failure of CL 218,872 to decrease 5-HT and
CA turnover indicates that the alterations in 5-HT and CA
metabolism produced by BDZs are probably not mediated via
an interaction with Type I BDZ receptors. It is still
unknown, however, whether BDZs are influencing biogenic
amine neurotransmission through binding to another subtype
among BDZ receptors (i.e., central Type II or brain located
peripheral type), or alternatively, through an as yet
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unidentified neural mechanism.
Taken together, the present findings using CDP and CL
218,872 indicate that behavioral sedation, as measured by a
decrease in either unpunished responding or locomotor
activity, can be evidenced without a concomitant decrease
in CA turnover. These results similarly reveal that
anxiolysis, as assessed by anticonflict activity, can be
demonstrated in the absence of a parallel reduction in 5-HT
turnover. Therefore, the data reported here are
inconsistent with and do not support the Wise et al . (1972)
hypothesis that reductions in brain 5-HT and NE activity
respectively can account for the anticonflict and sedative
effects produced by BDZs.
CHAPTER V
EXPERIMENT IV
ATTENUATION OF STRESS-INDUCED CORTICOSTERONE ELEVATIONS BY
ANXIOLYTIC DRUGS: A POSSIBLE ROLE FOR PERIPHERAL-TYPE
BENZODIAZEPINE RECEPTORS IN BRAIN
Introduction
One approach to studying the biochemical basis of
anxiety has suggested that anxiety may result from
biochemical changes induced by glucocorticoid hormones
secreted from the cortex of the adrenal glands. Evidence
from clinical studies has indicated that high concen-
trations of circulating glucocorticoids may increase
anxiety-proneness (Persky, 1966), and Warburton (1974)
proposed that anxiety-reducing agents such as
benzodiazepines (BDZs) may do so by antagonizing the
anxiety-inducing actions of glucocorticoids.
The hypothalamic-pi tui tary-adrenocortical (HPA) axis
can be stimulated by a variety of stressful stimuli,
including novel situations (File, 1982), sound (Torrellas
et al., 1980), handling (Marc and Morselli, 1969), light
(File and Peet, 1980), forced swimming (LeFur et al., 1979)
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and footshock (Thiebot et al.
, 1982). These stress-induced
glucocorticoid elevations can be blocked or attenuated by
pretreatment with relatively low doses of BDZs (above
references), or with other agents possessing antianxiety
activity such as diphenylhydantoin (Bonnycastle and
Bradley, 1959), meprobamate (Lahti and Barsuhn, 1974), and
barbiturates (Lahti and Barsuhn, 1975; Norton, 1971; Rerup
and Hedner, 1962). However, neither neuroleptics, psycho-
stimulants, antidepressants, anticholinergics, alpha- and
beta-blockers, serotonin receptor blockers, nor a narcotic
analgesic lowered corticosteroid concentrations in stressed
rats (LeFur et al., 1979; Lahti and Barsuhn, 1974),
illustrating the pharmacological specificity of this
action.
Relatively high doses of BDZs themselves elevate
glucocorticoid concentrations in unstressed rats (Torrellas
et al., 1980; Lahti and Barsuhn, 1975; Mark and Morselli,
1959), an effect reportedly related to the behaviorally
depressant action of these drugs (Lahti and Barsuhn, 1975).
Although some conflicting results regarding the effects of
chronic BDZ treatment on glucocorticoid secretion have been
reported, most investigators report that tolerance develops
to the BDZ-induced elevation in glucocorticoid concentra-
tions but not to their glucocorticoid attenuating action in
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stressed animals (for review, see Torrellas et al
. ,
1 980 ).
The presence of BDZ receptors in the adrenal cortex,
anterior pituitary, and other tissues outside of the brain
raises questions concerning the site of action of these
drugs on the HP A axis. Cor ti co s t erone increases produced
by a high dose of diazepam could be prevented by blocking
Pituitary ACTH release (Chabot et al., 1 9 81), indicating
that diazepam was not directly stimulating the adrenal
cortex in this situation. BDZ inhibition of stress- induced
glucocorticoid secretion probably also does not involve an
adrenal site of action, inasmuch as diazepam was unable to
prevent adrenocortical stimulation by exogenously adminis-
tered ACTH (Lahti and Barsuhn, 1974). Thus it appears that
the effects of BDZs (and probably other similarly acting
drugs) on adrenocortical secretion occur secondary to
changes in ACTH secretion. However, it is not yet clear
whether the BDZ receptors mediating such effects are
located in the brain, the pituitary gland, or in a non-
neuroendocrine tissue. Thus, one aim of the present
research was to determine whether BDZs influence cortico-
sterone secretion through a central (i.e., brain) or
peripheral site of action. To this end, serum cortico-
sterone concentrations were measured in sound-stressed and
in unstressed rats following systemic or intracerebro-
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ventricular (i.e. v.) chlordiazepoxide (CDP) administration.
The second goal was to determine whether the actions of
BDZs and other antianxiety agents on the HP A system could
be extended to the triazolopyridazine CL 218,872. For this
purpose, the effects of acute CL 218,872 administration on
corticosterone concentrations in stressed and unstressed
rats were studied. m all cases where positive results
were obtained with CDP or CL 218,872, the effects of
chronic drug pretreatment were examined to test for the
development of tolerance and/or cross- tolerance
. The final
aim of this investigation was to establish whether the
influence of BDZs on corticosterone secretion could be
related to one particular BDZ receptor type by means of
central- (Ro 15-1788) and peripheral- (Ro 5-4864 and PK
11195) type receptor antagonists. A portion of this work
was presented in abstract form (McElroy and Meyer, 1983).
Methods and Procedure
Animals
Adult male albino rats were bred in our laboratory
from stock animals obtained from the Holtzman Co. (Madison,
WI) and were housed in a temperature controlled room
o
(approximately 22 C) under a 14:10 light-dark cycle (lights
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on at 0600 far). Rats were housed in group cages until they
weighed 200-250 g, at which time they were removed to
single cages and handled daily for at least 5 days prior to
testing. Tap water and standard Purina Rodent Chow pellets
were available ad libitum.
Drugs
CDP (Roche) was dissolved in physiological saline,
whereas CL 218,872 (Lederle), Ro 15-1788 and Ro 5-4864
(Roche), and PK 11195 (Pharmuka) were suspended in a solu-
tion of 20* propylene glycol in water. Intraperitoneal
(i.p.) injections were given in a volume of 2 ml/kg body
weight, while i.e. v. injections were given in a volume of
25 ul.
Cannula implantation
The animals were anesthetized with Equithesin (3
mg/kg, Jensen-Salsbery
, Kansas City, MO) and a hole was
drilled in the skull 2.1 mm lateral to the sagittal suture
and 0.5mm posterior to bregma. Cannula guides were
constructed and implanted as described in McElroy et al.
(1984). The surgery was performed 48 to 72 hr prior to
i.c.v. drug administration. A microinjection unit was used
to deliver the injectant through an internal cannula (25
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gauge disposable needle) that extended 0.5 to 1.0 mm beyond
the tip of the guide cannula. The location of the cannula
in the lumen of the lateral ventricle was verified in all
animals by examining the stain produced by injecting a 0.1$
toluidine blue solution immediately after decapitation.
Procedure
Experiments were conducted between 0800 and 1200 hr to
ensure that baseline corticosterone concentrations would be
low. Rats (5-9 per group) were injected with drug or
control solutions at the time and dosage schedules
indicated in each figure and table legend. Sixty min after
systemic CDP or CL 218,872 injection, or 15 min following
i.c.v. CDP injection, animals were quietly transferred from
the animal room (one at a time, at 15 min intervals) to an
adjacent room where they were placed singly in an
unfamiliar test apparatus. The test apparatus consisted of
a standard operant chamber (Skinner box) enclosed in a
sound-attenuated, fan- ventilated enclosure. Each rat was
exposed to constant sound stimulation (120 dB ) produced by
a ceiling-mounted Sonalert. Following stress, the animals
were quietly removed from the test apparatus and quickly
decapitated. Unstressed rats remained in their home cages
for 75 min following drug administration, after which time
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they were quietly removed from the animal room and quickly
decapitated. Trunk blood samples were collected at the
time of decapitation, allowed to clot, centrifuged (2700
RPM for 10 min), and the serum either assayed immediately
or stored at
-40oC for subsequent corticosterone determin-
ation by radioimmunoassay (Meyer, 1983).
Data analysis
All data were subjected to analyses of variance
(ANOVA) followed by individual mean comparisons using
Fischer's Least Significant Difference Test (Kirk, 1968)
where appropriate. Results occurring with a chance
probability of less than .05 were considered statistically
significant
.
Results
Fig. 5 illustrates that placement in a novel environ-
ment and exposure to sound stimulation elevated blood
corticosterone concentrations in a time-dependent fashion
(F = 15.05, df = 4, 35, p < 0.001). Post-hoc testing
revealed that corticosterone concentrations were signifi-
cantly increased after 10, 15, or 30 min of exposure to
stress. Based on these results, 15 min of sound stimula-
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F1 S- 5. Effect of constant 120 dB sound
stimulation on serum corticosterone concentra-
tions in rats. Data represent the mean ( + 1
S.E.) for eight rats per group. *Groups that
differ significantly (at least p < 0.05) from the
control (0 min) group.
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tion served as the stressor in subsequent experiments.
The effects of different doses of systemically admin-
istered CDP on serum corticosterone in sound-stressed and
in unstressed rats can be seen in Fig. 6. ANOVA revealed
highly significant Stress (F = 27.08, df = 1, 50f p <
0.001) and Dose (F = 1 9 . 3 2, df = 4, 50, P < 0.001) main
effects, as well as a Stress x Dose interaction (F = 3.55,
df
= 4, 50, P < 0.05). In unstressed rats CDP elevated
corticosterone values in a dose-dependent fashion with the
10 and 20 mg/kg doses significantly different from the
control (0 mg/kg) group. In rats subjected to sound stimu-
lation, 2.5 to 10 mg/kg CDP attenuated the stress-induced
elevation in corticosterone, with the 5 mg/kg dose
significantly different from the control group. The
largest dose of CDP tested (20 mg/kg) produced a non-
significant enhancement of the corticosterone elevation
produced by sound stress.
The effects of i.e. v. CDP administration to sound-
stressed and to unstressed rats paralleled those observed
after systemic injection (Fig. 7). ANOVA revealed highly
significant Stress (F = 33-85, df = 1, 48, P < 0.001) and
Dose (F r 12.60, df = 5, 48, P < 0.001) main effects, as
well as a Stress x Dose interaction (F = 2.44, df = 5, 48,
P < 0.05). A low dose of CDP (5 ug) significantly atte-
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Fig. 6. Effect of various doses of systemically
administered chlordiazepoxide (CDP) on serum
corticosterone concentrations in sound stressed
rats. Animals were killed 75 min after drug or
vehicle injection and immediately after 15 min of
constant 120 dB sound stimulation. Data repre-
sent the mean (+ 1 S.E.) for six rats per group.
•Groups that differ significantly (at least p <
0.05) from the corresponding control (0 mg/kg)
group
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Fig. 7. Effect of various closes of i.e. v.
administered chlordiazepoxide (CDP) on serum
corticosterone concentrations in sound stressed
and in unstressed rats. Animals were killed 30
min after drug or vehicle injection and immedi-
ately after 15 min of constant 120 dB sound
stimulation. Data represent the mean (+ 1 S.E.)
for five rats per group. "Groups that differ
significantly (at least p < 0.05) from the
corresponding control (0 mg/kg) group.
104
nuated the stress induoed elevatlon 0orti003teronei
whereas relatively higher doses of CDP ( 25 and 50 ug)
elevated corticosterone conoentrations in unstressed rats.
As was observed following i.p. administration, the highest
dose of CDP tested (50 ug) produced a non-signlf ioant
enhancement of the corticosterone elevation produced by
sound stress.
The effects of different doses of CL 218,872 on circu-
lating corticosterone in stressed and in unstressed rats
are presented in Table 3 . In marked contrast to
the results with CDP, CL 218,872 (2.5 to 20 mg/kg) did not
alter the corticosterone elevation produced by sound
stress, and also failed to elevate baseline corticosterone
concentrations in unstressed rats (F = 0.47, df = 4, 50. P
= 0.75 and F = 0.25, df = 4, 50, P = 0
.
9 1 for the Dose main
effect and Stress x Dose interaction respectively).
Table 4 (leftmost two columns) shows the effects of 15
mg/kg CDP on serum corticosterone in unstressed rats 48 hr
after six daily pretreatments with eitherCDP (15 mg/kg) or
CL 218,872 (2.5 and 10 mg/kg). ANOVA disclosed highly
significant Test Treatment (F = 14.41, df = 1, 64, P <
0.005) and Pretreatment (F = 8.75, df = 3, 64, P < 0.005)
main effects, in addition to a Test Treatment x Pretreat-
ment interaction (F = 8.14, df = 3, 64, P < 0.005). A
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Table 3
.
Effect of CL218,8 7 2 on serum corticosterone
concentrations in unstressed and in sound-stressed
r ats
.
CL218, 872 Treatment Serum Corticosterone (ug/100 ml)(mg/kg)
Unstressed Sound Stressed
0
2.5
5.0
10
20
13.7 ± 2.6
14.1 + 3.8
14.4 + 3-9
10.7 ± 2.5
16.1 + 4.2
34.2 + 2.7
38.9 ± 6.6
32.9 ± 6.5
36.2 + 4.6
40.2 + 3.5
CL 218,872 was given 1 hr before the rats were stressed and
75 min before the rats were killed. Data represent the
mean +_ S.E. for 6 rats per group. No groups were
significantly different (at least p < 0.05) from the
corresponding control (0 mg/kg) group.
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Table 4. Effect of chlordiazepoxlde (CDP) or CL 218,872
pretreatments on A) the serum cortioosterone eleva-
tion produced by CDP in unstressed rats, and on B)
the CDP-induced attenuation of cortioosterone in
sound-stressed animals.
Pretreatment
(mg/kg)
Serum Cortioo sterone ( ug/1 oo m l)
Test Treatment.
ID. Unstressed XB1 Sound Stressed
CDp (15) vehicle CDPCn vehicle
Vehicle 35.2 11.8 20.1 39.8
±5.3 ±1 • 1 ±2.5 ±4.8
CDP (15) 11.3 12.2 20.0 37.9
±1 .0* ±0.9 ±1.9 ±5.0
CL218,872 (2.5) 19.6 14.6 25.
1
34 .
1
±4.7* ±2.0 ±4.3 ±3.4
CL218,872 (10) 12.2 10.4 27.3 43 .2
±1 .7* ±0.9 ±4.8 ±5.1
All test treatments were given 1 hr before the rats were
stressed, and 48 hr after 6 consecutive daily pretreat-
ments. Data represent the mean ± S.E. for 9 rats per
group. "Significantly different (at least p < 0.05) from
the corresponding vehicle pretreatment group.
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single test injection of CDP (column 1) produced a reliabl
corticosterone elevation in vehicle pretreated animal
(from 11.8 to 35.2 ug/100 ml), but not in rats pretreated
with either CDP or CL 218,872. Thus, prior CDP or CL
218,872 treatment produced tolerance and cross- tol erance
respectively to the CDP-induced elevation of corticoste-
rone. m vehicle tested animals (column 2), chronic
pretreatment with CDP, CL 218,872, or vehicle had no effect
on baseline corticosterone levels.
The effects of CDP (5 mg/kg) or CL 218,872 (2.5 and 10
mg/kg) pretreatment on the CDP-induced attenuation of
corticosterone secretion in sound-stressed rats can also be
seen in Table 4 (rightmost two columns). ANOVA revealed a
highly significant Test Treatment main effect (F = 26.72,
df
= 1 , 64, P < 0.001) but no Pretreatment main effect (F =
1.12, df = 3, 64, P = 0.35) or interaction (F = 0.92, df =
3, 64, P = 0.44). A single test injection of CDP (5 mg/kg)
reliably attenuated the hormone elevation produced by sound
stress (from 39.8 to 20.1 ug/100 ml). This CDP action was
not altered by prior CDP or CL 218,872 treatment, indica-
ting that neither tolerance nor cross- tolerance had
developed to this BDZ action. Corticosterone values in
vehicle tested animals were also not affected by CDP or CL
218,872 pretreatment.
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The effects of central- fRn k i 7 oq>dX 15-1788) and peripheral-
type (Ro 5-4864 and PK 11195) BDZ receptor antagonists on
the ability of CDP ( 5 mg/kg) to attenuate sound-induced
corticosterone elevations are presented in Table 5. One-
way ANOVAs disclosed no significant Dose effects for
either Ro 15-1788 (F = 0.4 3 , df = 4, 20, P = 0.73) or Ro 5-
4864 (F = 2.18, df = 5
, 24, P = 0.09), although there was a
tendency for higher doses of the latter drug to antagonize
the corticosterone lowering action of CDP. On the other
hand, a significant dose-related blocking of the CDP effect
was obtained with PK 11195 (F = 2.77, df = 5, 2 4, P <
0.05). Post-hoc testing revealed that both the 1 and 2
mg/kg doses were effective in this regard. When given
alone, neither Ro 15-1788 (5 and 20 mg/kg), Ro 5-4864 (2
and 8 mg/kg), nor PK 11195 (1 and 2 mg/kg) had any effect
on basline corticosterone concentrations in unstressed
rats (data not shown).
Pi scussion
It was previously established that novelty and/or
sound stimulation can produce an elevation in blood
glucocorticoid concentrations, and that BDZ pretreatment
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Table 5. Effect of Ro ,5-1788, Ro 5 -*864, or Plt ,„„
pretreatment on the chlordiazepoxide ( CDP )
-induced attenua-
tion of serum corticosterone In sound-stressed rats.
Pretreatment
(mg/kg) CDP(mg/kg) SerumCorticosterone
0 41 .6 ± 4.7*
Vehicle 5 23.3 ± 2.7
Ro 15-1788 (5) 5J 22 . 3 ±2.6
(10) 5 17.5 ±4.9
(20) 5 19.9 ± 5.2
Ro 5-4864 (1) 5 24.5 ±6.7
(2) 5 17.6 ± 3.3
(4) 5 33. 1 ± 10.4
(8) 5 36.7 ± 6.4
PK 11195 (0.25) 5 24.9 ± 3.6
(0.5) 5 21.6 ± 5.7
(1) 5 42.8 ± 5.8*
(2) 5 38.0 ± 9.4*
CDP was given 1 hr before rats were stressed and 30 min
after either Ro 15-1788, Ro 5-4864, or PK 11195
pretreatment. Data represent the mean + S.E. for 5 rats
per group, except all vehicle pretreated groups were com-
bined (N = 15) for purpose of presentation. *Signif icantly
different (at least P < 0.05) from the vehicle-CDP group.
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can prevent this action (File, 1982; Torrellas et al.,
1980). The present findings are consistent with these
reports. Fifteen min. exposure to a novel environment plus
sound stimulation produced a three-fold increase in
circulating corticosterone. Relatively low doses of CDP
(2.5 to 10 mg/kg) attenuated this stress-induced hormone
elevation, with the 5 mg/kg dose significantly reducing
corticosterone concentrations. In marked contrast to the
corticosterone lowering action produced by relatively low
doses, the highest dose of CDP tested (20 mg/kg) led to a
non-significant enhancement of the stress response.
Similar dose-dependent effects of BDZs upon the pituitary-
adrenocortical response to stress have previously been
reported (Lahti and Barsuhn, 1974; Torrellas et al
. ,
1980).
A single i.p. injection of CDP to rats not subjected
to stress was followed by a dose-dependent increase in
serum corticosterone concentrations. These results are in
general agreement with several other studies (Lahti and
Barsuhn, 1 975 ; LeFur et al .
, 1 979), although Krulik and
Cerby (1971) reported that subcutaneous administration of
CDP did not alter circulating corticosterone concentrations
in their animals. Nevertheless, it appears that the
overall effect of a given dose of CDP in stressed rats
depends on the interaction of two opposing tendencies. At
1 1
1
low doses, the drug acts to antagonize the pituitary-
adrenocortical stress response, while intermediate and high
doses mask this effect because of their tendency to
stimulate adrenocortical secretion even in the absence of
an applied stressor.
One aim of the present studies was to determine
whether BDZs influence pi tui tary-adrenocor tical activity
via a central (i.e., CNS) or peripheral site of action.
For example, these drugs could be acting in the hypothala-
mus, as central type BDZ receptors have been found in this
brain region (Mohler and Okada, 1977). On the other hand,
the notion that BDZs might be controlling glucocorticoid
secretion through a peripheral mechanism is not unreason-
able as both the 5-HT releasing drug fenfluramine (McElroy
et al., 1984) and the GABA-mimetic drug muscimol (Grandison
and Guidotti, 1979) have been found to influence pituitary
hormone release via peripheral receptors. Furthermore, the
identification of GABA and GABA receptors (Racagni et al.,
1982) along with the previously mentioned peripheral- type
BDZ receptors (Schoemaker et al
. ,
1983) in the anterior
pituitary strengthens the possibility that BDZs could
affect the pituitary-adrenocortical system by a direct
action at that level. However, we found evidence for a
central action of BDZs in that the effects of i.e. v.
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administered CDP in both st ressed and unstressed rats
paralleled those observed following systemic administra-
tion. A relatively low dose of CDP (5 ug) attenuated the
stress-induced elevation in corticosterone, while somewhat
higher doses of CDP (25 and 50 ug) elevated corticosterone
concentrations in unstressed animals. This 200-fold
increase in potency of centrally- vs. sy stemically-
administered CDP supports the hypothesis of a CNS site of
BDZ action, although we cannot completely rule out the
possibility that small amounts of the drug reached the
Pituitary gland via the pituitary portal circulation.
Further studies will be necessary to resolve this issue.
Attenuation of stress-induced glucocorticoid responses
has been observed with other antianxiety agents such as
meprobamate (Lahti and Barsuhn, 1974), diphenylhydantoin
(Bonnycastle and Bradley, 1959), and barbiturates (Lahti
and Barsuhn, 1974; Norton, 1971). However, neuroleptics,
psychostimulants, antidepressants, anticholinergics, alpha-
and beta-blockers, 5-HT receptor blockers, and a narcotic
analgesic did not reduce circulating corticosterone conce-
ntrations in stressed rats (LeFur et al
. , 1979; Lahti and
Barsuhn, 1974), demonstrating the pharmacological specifi-
city of this action. These findings led Lahti and Barsuhn
(1974) and LeFur et al
. (1979) to propose that the corti-
113
costeroid stress test could be used to screen Tor potential
antianxiety agents. The present experiment evaluated this
hypothesis by examining the effects of CL 218,872, a novel
anxiolytic compound of the triazolopyridazine class, on the
Pituitary-adrenocortical system. CL 218,872 did not atten-
uate the corticosterone elevation produced by sound stimu-
lation, and also failed to alter baseline corticosterone
concentrations in unstressed animals. These results indi-
cate that stress (as measured by pituitary-adrenocortical
activation) can be dissociated from anxiety (as measured
for example by conflict paradigms), thus challenging the
validity of the corticosterone test as a screening
procedure for anxiolytic activity. Whether or not the
results obtained here are unique to CL 218,872 or can be
extended to pharmacologically similar anxiolytic compounds
such as zopiclone (Wickstrom and Giercksky, 1980) or PK
9084 (LeFur et al
. , 1981) remains to be determined.
Previous studies report conflicting effects of
prolonged BDZ administration on circulating corticosteroid
concentrations. For example, it was reported that
tolerance develops to the diazepam-induced rise in serum
corticosterone in unstressed rats, but not to the drug's
glucocor ticoid-attenuating action in stressed rats (Lahti
and Barsuhn, 1 975). On the other hand, Torrellas et al
.
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(1980) showed the development of tolerance to both BDZ
effects, whereas Marc and Morselll (1969) demonstrated no
tolerance to the elevation of corticosterone produced by
high doses of diazepam in unstressed rats. I„ the present
experiment, six daily CDP pretreatments produced tolerance
to the elevation in plasma corticosterone triggered by
acute administration of the drug. I„ marked contrast,
however, chronic drug treatment did not affect the ability
of a subsequent CDP injection to antagonize the cortico-
sterone elevation produced by sound stress. Thus, our
results are consistent with those of Lahti and Barsuhn
(1975). The discrepancies between the various reports
cited here are probably a consequence of the numerous
differences in experimental conditions (i.e., choice of
stresor, choice of BDZ, mode of drug administration, and
number of drug treatments), and may simply reflect the
extreme lability of the H PA system.
CL 218,872 pretreatment had the same effect on a
subsequent challenge injection of CDP as did CDP pretreat-
ment itself. Specifically, six daily injections of CL
218,872 (2.5 and 10 mg/kg) did not impair the ability of a
low dose of CDP (5 mg/kg) to attenuate the corticosterone
elevation produced by sound stress, whereas this same pret-
reatment regimen did prevent the enhanced corticosterone
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secretion Produced by a relatively large dose of CDP ( 15
mg/kg) in unstressed rats. The latter effect demonstrates
cross-tolerance by CL 218,
8
7 2 to the glucocorticoid eleva-
ting action of CDP, and is particularly interesting because
this dose of CL 218,872 did not itself affect corticoste-
rone concentrations. Chronic CDP (Hoogland et al., 1 966 )
or ethanol (Sellers and Busto, 1982) treatment has been
reported to decrease the blood concentration of
subsequently administered CDP, indicating that tolerance
and cross-tolerance to the effects of CDP can be a result
of enhanced hepatic metabolism of the drug. it is not yet
clear whether the tolerance and cross- tolerance reported
here are enzymatic, cellular, or behavioral in nature.
Overwhelming biochemical, pharmacological, and
behavioral evidence suggests that classical brain-specific
BDZ receptors mediate at least the anxiolytic and anticon-
vulsant actions of this class of drugs (Tallman et al.,
1 980 ; Schallek et al
. , 1 979 ; Braestrup and Squires, 1 978).
The physiological relevance of peripheral- type BDZ recep-
tors, however, is still unclear. The present studies
attempted to determine which BDZ receptor type mediates the
pi tuitary-adrenocortical actions of BDZs. To this end,
several compounds with well defined interactions with BDZ
receptors were evaluated for their effects on the cortico-
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sterone response to stress. As mentioned above, CL 218,872
did not produce a BDZ-li ke action in either stressed or
unstressed rats. As this compound is known to be an
agonist at central Type I BDZ receptors (Squires et al
.
,
1979), it appears that BDZs are not exerting their
Pituitary-adrenocortical actions via stimulation of such
receptors. Moreover, Ro 15-1788, a BDZ antagonist specific
for brain-type BDZ receptors (Mohler and Richards, 1981),
failed to prevent the CDP effect in stressed rats. Consis-
tent with these results, brief or prolonged exposure to
physiological or psychological stress had little, if any,
effect on brain-type BDZ receptor binding (Braestrup et
1979; LeFur et al
. , 1979).
In marked contrast, however, the peripheral- type BDZ
receptor antagonist PK 11195 (LeFur et al., 1983a) fully
prevented the CDP effect in stressed rats. Our results
using Ro 5-4864, another ligand for peripheral- type BDZ
receptors (Braestrup and Squires, 1977), were less
conclusive as Ro 5-4864 did not block this CDP action but
only produced a non-significant trend in that direction.
The ineffectiveness of Ro 5-4864 may be due to the mode of
administration in that Weissman et al. (1983) recently
reported that the potency of this compound is reduced when
administered as a suspension (present experiment).
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Alternatively, our negative results using Ro 5-4864 may be
explained by thermodynamic studies suggesting that PK 11195
is an antagonist, while Ro 5-4864 is a full or partial
agonist at peripheral- type binding sites (LeFur et al.,
1983a). Nonetheless, the results reported here indicate
that CDP is altering cor ti co sterone secretion via binding
to peripheral-type BDZ receptors. Taken together with the
evidence that CDP is exerting this action at a CNS
location, our results implicate peripheral- type receptors
in brain as the target sites through which BDZs influence
glucocorticoid secretion. This is one of the first physio-
logical roles postulated for peripheral- type BDZ receptors
in rat brain.
Bizzi et al
.
( 1 983 ) recently reported that Ro 15-1788
reversed the effect of diazepam on plasma corticosterone in
stressed rats, results at odds with those reported here.
Aside from numerous methodological differences between the
two studies, we cannot reconcile these disparate findings.
However unlikely, the possibility exists that CDP and
diazepam are exerting their corticosteroid actions through
separate sites and/or receptor types. Resolution of this
issue will certainly require further investigation.
Evidence for a widespread interaction between BDZs and
several hormonal systems has been growing in the last few
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years. For example, parallel to their effects on the
Pituitary-adrenocortical system, BDZs also inhibit stress-
induced prolactin secretion (Grandison, 1 9 8la), with this
effect similarly persisting even after chronic drug
administration (Grandison, 1 9 8lb). m contrast to these
inhibitory effects on hormone secretion, BDZs stimulate
growth hormone release both in vivo (Laakmann et al
. ,
1 982 )
and in vitro (Acs et al., 1 984) . BDZ regulation of
Pituitary hormone secretion may in some cases be related to
the presence of peripheral- type BDZ receptors in this gland
(Schoemaker et al
. , 1983)
There is also evidence for multiple interactions
between BDZs and hormone binding sites and between various
hormones and BDZ receptors. Thus, thyrotropin-releasing
hormone binding in anterior pituitary, retina, and amygdala
was inhibited by micromolar concentrations of CDP and
diazepam, but not by clonazepam, Ro 15-1788, B-CCE, or 44
other neuroactive substances tested (Sharif et al., 1983).
In other experiments, L-thyroxine (Nagy and Lajtha, 1983)
and N-acety 1-5-methoxy ky nur enamine , a brain metabolite of
melatonin (Marangos et al., 1982), were found to have
higher affinities for BDZ receptors than any of the several
hundred other compounds that have been tested to date
(Braestrup and Squires, 1978; Mackerer et al., 1978;
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Marangos et al
. . iQA-n T f ^„ .»1981). It is interesting to note that of
all the endogenous compounds evaluated for their relative
potencies at peripheral- vs. central-type BDZ receptors (L-
thyroxine not included), only melatonin was a more potent
inhibitor of binding at the peripheral- type sites (Marangos
et al., 1982). This finding is of particular interest
considering the relatively high concentration of these
sites observed in the pineal gland (Weissman et al., 1983 ).
Finally, both melatonin (Sugden, 1983) and thyrotropin-
releasing hormone (Vogel et al -loamv 6 x u x., 1980) possess some
Pharmacological effects characteristic of BDZs. The above
results have led investigators to speculate that one of
these hormones, one of their metabolites, or perhaps a
structural analog might be an endogenous ligand for BDZ
receptors (Nagy and Lajtha, 1983; Holmes and Sugden, 1982;
Marangos et al
. , 1981). Verification of this hypothesis
awaits further investigation.
GENERAL SUMMARY
The present series of experiments profiled the non-BDZ
anxiolytic compound CL 2 1 8 ,
8
7 2. Specifically, this inves-
tigation examined the ability of CL 21 8
,
8
7 2, as compared to
the BDZ chlordiazepoxide (CDP), to 1) produce a discrimi-
native stimulus complex; 2) alter 5-HT and CA turnover
rates in brain; and 3 ) prevent stress-induced elevations
in serum cor ticosterone
. The rationale for these experi-
ments was three-fold. First, because the TPZs may ulti-
mately be of great value in the clinical treatment of
anxiety disorders, it was considered important to learn
more about the behavioral, neurochemical, and endocrine
actions of this class of drugs. Secondly, as agonists
selective for Type I BDZ receptors, the TPZs represent a
new probe for further clarifying the molecular basis by
which BDZs induce their various behavioral and physiologi-
cal actions. Lastly, since the above behavioral, neuroche-
mical, and endocrine actions produced by the BDZs have each
been considered either predictive of, or responsible for,
the anxiolytic potential of this class of drugs, CL 218,872
presents an opportunity either to confirm and extend or to
refute the validity of such measures as indicators of a
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drugs, clinical (anxiety reducing) potential.
In the first experiment rats were trained to
discriminate CDP from saline using a two-lever operant
procedure. An acute injection of CL 2 1 8,
8
7 2 elicited CDP
lever selection in a dose-dependent fashion, demonstrating
that CL 218,872 produces a discriminative stimulus similar
to that produced by CDP. The ability of a drug to
generalize to the CDP discriminative stimulus had
previously been restricted to barbiturates and other BDZs,
agents with clinical efficacy in the treatment of anxiety
disorders. Therefore, the present results are consistent
with, and further extend, the notion that the BDZ drug
discrimination paradigm can be utilized to screen for
potential anxiolytic agents. Furthermore, because CL
218,872 is an agonist selective for Type I BDZ receptors,
these results suggest that the discriminative stimulus
produced by BDZs may be mediated via an interaction with
this BDZ receptor subtype. Finally, the demonstration that
10 mg/kg CL 218,872 virtually abolished responding (as
measured by lever pressing for a milk reinforcement) is at
odds with a previous report that a much larger dose (223
mg/kg) is required to reduce locomotor activity by 50
percent (Lippa et al
. ,
1979).
The second experiment attempted to resolve this
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discrepancy by examinlng theeffectsof CL ^
locomotor activity in a conventional activity chamber.
Acute thirty min CL 218,872 pretreatment (10 mg/ kg i. p .)
significantly reduced locomotor activity, a finding in g00 d
agreement with that reported in Experiment I, but still at
variance with that reported by Lippa et al. ( 1979) .
However, it is possible that this 20-fold disparity in drug
potency may still be a result of methodological differences
since their drug to test interval was 60 min and they
administered CL 218,
8
7 2 by the oral route. The principle
finding of this experiment, however, was that CL 218,872 as
used in the present series of investigations is not devoid
of depressant side effects as was originally reported
(Lippa et al
.
, 1 979) .
The third experiment showed that acute administration
of CDP decreased the turnover (synthesis) rate in midbrain-
hindbrain of serotonin (5-HT), but not that of
catecholamines (CA), whereas chronic CDP treatment
decreased the turnover rates of both neurotransmitters. In
marked contrast, whether administered acutely or
chronically, CL 218,872 did not alter baseline 5-HT or CA
turnover rates. These results indicate that stimulation of
Type I BDZ receptors is not sufficient to decrease 5-HT and
CA turnover rates, and more importantly these results do
1 23
s
CA
not iend support to the Wise et al. ( ,„„ hypotnesi
suggesting that the anxiolytic and sedative effect
produced by BDZs are mediated via reductions in 5-HT and
turnover respectively.
The final experiment confirmed that a low dose of CDP
attenuated the increase in serum corticosterone produced by
exposure to a novel environment plus sound stimulation.
Somewhat higher doses of CDP elevated corticosterone levels
in unstressed rats. Parallel results were obtained after
central drug administration. CL 218,872, however, did not
attenuate the corticosterone elevation produced by stress,
and also failed to alter baseline corticosterone concentra-
tions in unstressed rats. Additionally, the CDP effect in
stressed rats was fully prevented by PK 11195, a receptor
antagonist specific for peripheral- type BDZ receptors, but
not by Ro 15-1788, an antagonist specific for central-type
BDZ receptors. Taken together, these findings implicate
peripheral-type BDZ receptors in brain as the target sites
through which BDZs influence corticosterone secretion.
Furthermore, the results using CL 218,872 are inconsistent
with the notion that the corticosterone stress-test can be
utilized to predict the efficacy of a compound as an
anxiolytic agent.
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